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ABSTRACT 
Background 
Multidrug-resistant tuberculosis (MDR-TB) is a threat to global tuberculosis (TB) control. Its 
management in human immunodeficiency virus (HIV) co-infected patients has been a 
challenging experience. There is however paucity of data on the effects of antiretroviral 
treatment (ART) before or after starting MDR-TB treatment. Therefore the objectives of 
this study were to describe the clinical characteristics and outcomes of MDR-TB treatment; 
and determine the predictors of mortality, cure and failure in HIV-TB co-infected patients 
who were started on ART before and after commencement of MDR-TB treatment. 
Methods 
A retrospective review of medical records of 1,200 MDR-TB HIV co-infected adults from 
Sizwe Tropical Disease Hospital from 2007 to 2010. The relationship between outcomes of 
MDR-TB treatment and independent covariates including receiving ART before or after 
commencement of MDR-TB treatment were assessed using chi-square test or Fisher’s exact 
test, and the t-test or the Mann-Whitney test where appropriate. Multivariable logistic and 
Poisson regression models were used to determine predictors of mortality, cure, and failure. 
Results 
Outcomes did not differ significantly by timing of ART initiation except for mortality which 
was higher among patients who started ART before (21.8% vs. 15.4%) MDR-TB treatment 
initiation (p = 0.013). Factors significantly associated with mortality included: the use of 
ART before commencement of MDR-TB treatment (OR: 1.76; [1.07-2.91]), being severely 
underweight (OR: 3.46; [1.77-6.77]) and underweight (OR: 2.31; [1.28-4.15]), cavitary 
lesions on baseline chest x-rays (OR: 1.83; [1.13-2.96]), presence of other opportunistic 
infections (OR: 1.85; [1.13-3.00]) and the presence of other co-morbidities (OR: 2.51; [1.34-
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4.68]). For predictors of cure, there was a significant interaction term between timing of ART 
initiation and gender (p = 0.002).  
Factors that positively predicted cure were male patients on ART prior to commencement of 
MDR-TB treatment (OR: 2.97; [1.47-5.99]), age ≥46 years (OR: 1.65; [1.05-2.59]), and CD4 
counts between “150-349” (OR: 1.85; [1.26-2.72]) and” ≥350” (OR: 1.76; [1.02-3.04]) 
cells/mm³. Negative predictors of cure included: the presence of cavitary lesions on baseline 
chest x-rays (OR: 0.55; [0.39-0.79]), and modified individualised regimen at baseline (OR: 
0.62; [0.42-0.92]).  Risk factors for failure included: severe anaemia (IRR: 3.94; [1.20-
12.89]) and modified individualised regimen at baseline (IRR: 2.25; [1.02-4.95]). 
Discussion and Conclusions 
This study is unique as it provides new information while also reinforcing old knowledge to 
clinicians and public health practitioners for the identification of TB populations at higher 
risk of death, treatment failure and decreased cure. High mortality among patients who were 
already on ART before commencement of MDR-TB treatment raise concerns about general 
ART adherence and monitoring at different HIV clinics across Gauteng Province.  
Clinicians should not undervalue the role of adherence to ART treatment in patients on ART 
before commencement of MDR-TB treatment. Management of existing adverse events, 
opportunistic infections and co-morbidities in these patients are important to maximise the 
protective benefits of being on ART before commencement of MDR-TB treatment. There is 
need to intensify intervention programmes targeted at increasing adherence and drug 
monitoring among HIV co-infected MDR-TB patients.  
Key words: Multidrug Resistant Tuberculosis (MDR-TB), Human Immune-deficiency virus, 
Antiretroviral Treatment, ‘HIV co-infected MDR-TB’. 
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CHAPTER 1: INTRODUCTION   
This chapter gives an overview of the burden of tuberculosis (TB) and multidrug-resistant TB 
(MDR-TB), as well as the rationale for the study and ends with an explicit review of relevant 
literature on the subject. 
1.1 Background 
Globally, there were an estimated 8.6 million incident cases of TB in 2012 of which 13% 
were co-infected with Human immune-deficiency virus (HIV) (1). Out of these, 1.3 million 
TB-related deaths were recorded with about 320,000 deaths in HIV co-infected individuals 
and 940,000 among HIV-negative TB patients (1). About 75% of the TB cases among HIV-
infected patients occurred in Africa. South Africa and Swaziland had the highest TB 
incidence rate of about 1 case per 100 persons each year (1).  
TB is primarily a disease of the lungs caused by an organism called Mycobacterium TB 
(MTB) and could present as a latent or active disease. It is the leading cause of death from 
infectious diseases especially amongst people living with HIV and Acquired 
Immunodeficiency Syndrome (AIDS) (1, 2).  The spread of the bacilli to other parts of the 
body including lymph nodes, gastro-intestinal tract, viscera, kidneys, bones and the central 
nervous system  results in extra pulmonary TB (EPTB), which can be treated with the 
conventional first line  anti-tuberculous agents.  
About 450,000 incident MDR-TB cases were diagnosed globally among pulmonary TB 
(PTB) patients in 2012 (1), which is an increase compared to 2011 (320,000 cases) (3). South 
Africa has the world’s third highest TB and drug resistant TB (DR-TB) burden (1). DR-TB 
develops as a complication of poorly treated TB and as a consequence of deficiencies in TB 
control programmes (4-6). From the 2013 World Health Organisation (WHO) global estimate 
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of TB cases, about 3.6% of the new cases and 20.2% of previously treated patients have been 
estimated to have MDR-TB (1).  
MDR-TB is defined as TB caused by MTB resistant in vitro to the effects of Isoniazid (INH) 
and Rifampicin (R), with or without resistance to any other drug. It could arise also from 
primary infection. Extensively drug resistant TB (XDR-TB) is defined as MDR-TB plus the 
resistance to any of the fluoroquinolones and any one of the second-line anti-tuberculous 
injectable drugs (Amikacin (AM), Kanamycin (KM) and Capreomycin (CM)). Treatment of 
DR-TB is expensive and takes a longer duration of at least 18-24 months. The most common 
treatment regimen for MDR-TB utilises five drugs namely KM/AM, Moxifloxacin (MFX), 
Ethionamide (ETO), Terizidone (TDR), Ethambutol (EMB) and Pyrazinamide (PZA) for at 
least 6 months during the intensive phase (IP), followed by at least  18 months of 
MFX/ETO/PZA/TDR after culture conversion for the continuation phase (CP) (7). Treatment 
is done first on an in-patient basis (not applicable to decentralised treatment centres) for at 
least 6 months (IP) while monitoring for sputum culture conversion until after conversion, 
and subsequently CP. 
1.2 Statement of the problem  
MDR-TB poses a threat to global TB control programmes (8), and this is aggravated in 
resource limited and low-income countries due to inadequate availability of prompt 
diagnostic and treatment measures (9). The incidence of MDR-TB has been shown to be 
rising especially among HIV positive patients in Sub-Saharan Africa (SSA), even though the 
incidence of TB has been noticed to be declining (1).  The co-infection of MDR-TB and HIV 
has been aptly described by Wells et al. as the “Perfect storm” (10).  About 170,000 of the 1.3 
million TB deaths globally in 2012 were due to MDR-TB (1). 
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South Africa is included as one of the countries by the WHO to have over 80 percent of 
notified estimated MDR-TB cases worldwide with about 10,085 notified cases in 2012 (1). 
The 2001/2002 TB drug-resistant survey conducted by the Medical Research Council of 
South Africa revealed that 1.6% of patients with newly diagnosed TB and 6.6% of patients 
previously treated for TB had MDR-TB isolated from their sputum (11). This data may not be 
correct anymore as results of the on-going drug-resistant survey is being awaited.  In South 
Africa the MDR- and XDR-TB epidemic have mainly been driven by the HIV epidemic and 
inadequate airborne infection control (12). It has been reported that over 80 percent of MDR- 
and XDR-TB patients in South Africa are HIV positive (13). The rapid spread of MDR-TB 
among HIV-positive patients is due to the impaired ability of the immune system to contain 
the MDR-TB bacilli in these patients as this applies also to the normal TB bacilli (14). The 
probability of progression from latent TB to active disease is 20-30 times higher in HIV 
infected individuals compared to those uninfected (15). 
Diagnosis and treatment of MDR-TB has been quite a challenging venture around the globe 
especially in the resource limited settings (RLS). This is even more difficult among HIV-
infected individuals as the classical symptoms of PTB may not be as pronounced as in HIV 
negative patients. Also HIV positive patients are sometimes smear negative, hence 
presentations of TB amongst these patients may be over-looked and attributed to the HIV 
infection.  Further difficulties in early diagnosis can be ascribed to delays in results of drug 
susceptibility testing (the gold standard for diagnosis of MDR-TB) which is sometimes not 
feasible at baseline for all patients. The adverse events from lifelong treatment of HIV with 
antiretroviral therapy (ART) coupled with side effects from MDR-TB drugs makes the 
management and outcomes of MDR-TB in co-infected patients a nightmare for most 
physicians.  
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1.3 Justification 
 Studies have compared treatment outcomes of MDR-TB with documentations of fatal and 
poor outcomes in co-infected patients prior to the scaling up of ART (16-18). Studies 
conducted after the roll-out of ART reveal better outcomes for MDR-TB (19-21); however, 
these studies were done to ascertain outcomes of MDR-TB for both HIV infected and 
uninfected individuals with the number of enrolled HIV-positive patients ranging between 40 
to less than 300 not considering the timing of ART initiation. Research work carried out on 
timing of ART initiation in patients with pan susceptible TB used ARV-naïve TB patients 
(22), without looking at the effect of ART initiation before the start of TB treatment. 
 There is paucity of   studies conducted in SSA on the effect of timing of ART initiation 
before or after commencement of MDR-TB treatment on MDR-TB outcomes in HIV positive 
patients. Data on this is highly needed in order to help evaluate the efficiencies/deficiencies 
of MDR-TB treatment and ART programmes. Therefore it is essential to ascertain the role 
timing of introduction of ART plays in the management of patients with MDR-TB and HIV 
co-infection. Such findings would be used to guide policy change so as to improve MDR-TB 
treatment among HIV co-infected patients in South Africa. 
 1.4 Research question 
What are the effects of timing of ART initiation on the treatment outcomes of MDR-TB in 
TB-HIV co-infected patients in South Africa? 
5 
 
1.5 Literature review 
1.5.1 General effect of the HIV epidemic on treatment outcomes of TB- pre and post 
TB-ART integration programmes 
TB treatment in HIV co-infected patients has evolved over the years. A lot of controversies 
exist due to the complications associated with the treatment. High case fatality rates (CFR) 
were documented despite effectiveness of anti-tuberculous drug treatment (23, 24). Mukadi 
YD et al. demonstrated higher CFR in smear negative and extra-pulmonary patients than in 
smear positive cases (23). They attributed this increased mortality to HIV-related diseases 
and not necessarily TB and to the increased demands of the HIV epidemic on the general 
healthcare services and delivery in-terms of facility/material resources and man-power (23). 
It must be noted, however, that these studies were done before the integration of HIV-TB 
treatment programmes.  
Following the integration of TB-HIV treatment, problems evolved around the ideal initiation 
time of ART during TB treatment. This was due to the increased rates of Immune 
Reconstitution and Inflammatory Syndrome (IRIS) in HIV co-infected patients who had very 
low CD4 cell count. IRIS has been shown to be associated with early initiation of ART and 
could increase mortality in these patients (25-27), but Karim SS et al. had little or no deaths 
attributable to IRIS. This could also be due to the fact that mortality in their study was 
characterised as all cause (28). There is mounting evidence of improved treatment outcomes 
of TB with early ART initiation, notable among them is the clinical trial done by Karim SS et 
al. (28, 29). 
1.5.2 MDR-TB outcomes, HIV co-infection and ART 
Systematic reviews and meta-analysis results based on data from different continents and 
over 21 countries have revealed a relatively low successful MDR-TB treatment outcome of 
about 62-64% (30, 31). For these studies, successful treatment was defined as a combination 
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of cure and “treatment completed” based on the WHO classification of treatment outcomes.  
Both studies also had similar levels of outcomes in terms of failure (6-8%), default (12-13%), 
died (11%) and transferred out (2%) (30, 31). However, the study by Orenstein EW et al. 
combined transferred out and defaulted treatment as one outcome. The review by Orenstein 
EW et al. included only two of the 22 high TB burden countries and had no study from SSA, 
but Johnston JC et al. included one study from SSA where the incidence of MDR-TB and the 
prevalence of HIV are different from the rest of the included populations [this was a 
randomised control trial conducted in South Africa between 1992-2002; a study by Shean KP 
et al. (32)] (31). These reviews also had inconsistently reported HIV status from the pooled 
studies used.  
A recent large individual patient data meta-analysis consisting of 9153 patients (33) 
documented very low proportion of treatment success which was slightly more than half of 
the patient population (54%) compared to other treatment outcomes (33). This study utilised 
data from three systematic reviews (30, 31, 34). The proportion of patients that died in the 
study was 15% and these were mainly older HIV positive patients.  All of the aforementioned 
studies did lack data on the use of antiretroviral drugs.  
In SSA, several studies have compared treatment outcomes of MDR-TB, in terms of cure, 
completed treatment, failure, default, and mortality between HIV co-infected patients and 
HIV negative patients, with documentations of poor and sobering outcomes in co-infected 
patients prior to the scaling up of ART (16-18). Data from this region especially from studies 
conducted in South Africa revealed much lower and poorer treatment success rates of about 
43-46% (16-18), higher and earlier mortality rates of over 23% especially among HIV co-
infected patients (16), higher default and treatment failure using a standardized treatment 
regimen when compared to the meta-analyses (30, 31) that used more studies with 
individualised treatment regimen than the standardised regimen. 
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Following the roll out of ART in SSA, there have been favourable treatment outcomes of 
MDR-TB among HIV co-infected patients with comparable and no statistically significant 
difference in the outcomes between negative and positive patients (19-21, 35). In a South 
African study by Brust JC et al., overall treatment success has been as high as 77% with the 
proportion of patients who died estimated to be as low as 6% and better retention in care with 
a minimal default rate of about 5% (19). The improved outcome in this study was attributed 
to the decentralised integrated, home-based MDR-TB/HIV treatment programmes (19). 
Similar results in terms of higher proportion of culture conversion were reported by Loveday 
M et al., using the same treatment model compared with centralised care (35). In this study, 
this difference was attributed to the shorter median time to MDR-TB treatment initiation and 
tight follow-up scheme adopted by the decentralised programme (35). However, there was no 
statistically significant difference in the probability of survival in patients using both models 
(35). Similar but lower proportions of default and treatment failure have also been noted in 
studies conducted in other parts of Southern Africa (20). 
A study conducted in Lesotho by Satti H et al. with 134 MDR-TB patients out of which 94 
(70%)  were co-infected with HIV showed no difference in outcomes in terms of the 
proportion of deaths among the HIV/MDR-TB co-infected adults based on the timing of ART 
initiation, compared with patients not on ART (20). Nevertheless, it was noticed that the 
median survival time for those who were not started on ART after MDR-TB treatment 
initiation was shorter compared with those who commenced ART prior to or during MDR-
TB treatment (80 vs. 138 days, p = 0.065); although patients who started ART after initiating 
MDR-TB treatment did so within a median duration of 16 days (20). Failure of achieving 
statistical significance in this study may have been due to the limited sample power.  A 
common ground for these studies was comparison between HIV positive and negative 
patients. Only a few studies have reported outcomes of MDR-TB with concomitant ART 
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treatment in a high HIV prevalence setting from a cohort of HIV co-infected patients (36-38). 
This appears to be the first retrospective medical record review ascertaining treatment 
outcomes involving such a large cohort of only HIV positive MDR-TB patients.  
1.5.3 Predictors of cure, failure and mortality 
There are several factors that may predict poor outcomes of MDR-TB in general and more so 
among HIV co-infected patients. These are important because intervention can be modified 
based on these factors to improve treatment outcomes. Factors associated with poor treatment 
outcomes include male gender, smear positivity during diagnosis, low BMI, alcohol abuse, 
fluoroquinolones resistance, presence of XDR strains (31, 33, 39), and CD4 count <200 
cells/mm³ (40); while individualised treatment regimen compared with standardised treatment 
regimen (30), history of no previous treatment and surgical intervention (30), have been 
associated with successful treatment outcomes. The majority of studies on outcomes of 
MDR-TB report cure and treatment completed as ‘successful treatment’; but this study 
reports each outcome as a mutually exclusive entity since technically, the one does not denote 
the other. 
Predictors of mortality and treatment failure include weight less than 60 kg (16), low/severely 
low body mass index (BMI) (16, 20, 31, 36, 41, 42), history of working in South Africa (20), 
and relapsed TB (43). Severe chest radiographic findings like cavitation have been associated 
with longer time to sputum conversion hence poorer outcomes like mortality and failure (43-
45); however, some studies found no association between cavitary lesions and poorer 
outcomes (31, 46). Low baseline weight is documented to result in a 3-fold increase in the 
hazard of mortality compared with normal baseline weight (36). The presence of other co-
morbidities has also been identified as a risk factor for mortality (47) in a study conducted in 
the United Kingdom. By examining the varying effects of ART on mortality, receiving ART 
has been shown to significantly lower mortality compared with patients not on ART (36).  
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1.5.4 Outcomes in MDR-TB/HIV co-infected patients based on the timing of initiation of 
ART 
There have been few reported studies looking at the effect of timing of (early) initiation of 
ART on the outcomes of MDR-TB treatment in HIV positive patients (36, 38), but none in 
SSA. Palacios E et al. noted a lower death rate in HIV positive patients who had started ART 
early compared to those who were not on ART with receiving ART predicting a lower hazard 
of mortality (36).   Nonetheless, the median time for ART initiation was longer, about 5.6 
months, and this study had patients not on ART as a comparison group. Similar results were 
obtained in a study by Waisman JL et al. who compared mortality in MDR-TB HIV positive 
patients prior to availability of HAART and during the HAART era; with a limited sample 
size of 43 patients (37). These studies did not consider timing of ART based on before or 
after initiation of MDR-TB treatment. Early initiation of ART during MDR-TB treatment has 
been shown to produce favourable outcomes in terms of longer median survival time (20). 
ART has been shown to confer a protective effect on mortality in HIV patients on MDR-TB 
treatment (36), and this evidence supports the current WHO guidelines on commencing 
ARTs within 2-8weeks after commencement of MDR-TB irrespective of the CD4 count (48), 
compared to that which was in operation prior to 2010 of which ART was initiated in patients 
with CD4 cell count less than 350 cells/mm3. Isaakidis P et al. reported improved overall 
outcomes with an increase in the median CD4 count (after one to two years of treatment) of 
co-infected patients, majority of who were on ART before initiation of MDR-TB treatment 
(38).  Hence, adequate data is needed in SSA on the outcomes of MDR-TB in HIV positive 
patients who commenced ART before commencement of MDR-TB treatment compared to 
those who commenced ART after, to support the timely initiation of ART and improve the 
overall outcomes of MDR-TB in co-infected patients.  
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1.6 Study aim 
 The aim of the study was to determine the effect of timing of ART initiation on the treatment 
outcomes of MDR-TB in TB-HIV co-infected patients and the associated independent 
predictors of mortality, failure and cure. 
1.6.1 Specific objectives 
1. To describe the demographic and clinical characteristics of MDR-TB HIV co-infected 
patients initiated on ART before or after commencement of MDR-TB treatment at Sizwe 
Tropical Disease Hospital in Johannesburg, South Africa, from 1
st
 January, 2007-31
st
 
December, 2010.  
2. To determine and compare the outcomes of MDR-TB (cure, completed treatment, 
transferred out, defaulted, failed treatment, still on treatment and died) in HIV co-infected 
patients who were initiated on ART before and after commencement of MDR-TB treatment. 
3. To investigate the relationship between varying time of receiving ART (before or after 
commencement of MDR-TB treatment) with cure, failure, and mortality adjusting for 
potential confounders such as age, BMI, haemoglobin level, CD4 count, the presence of 
fibrotic changes or cavities on chest radiographs and other opportunistic infections, etc.  
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CHAPTER 2: METHODS 
In this chapter, the study design, study population and setting and selection of the study site, 
sampling and selection of the patient population, measurements and data sources are 
reviewed in detail. The key definitions, quality control, data management and analysis, and 
ethical considerations are also discussed. 
2.1 Study design 
This was a retrospective review of medical records of all HIV positive MDR-TB patients 
seen at Sizwe Tropical Disease Hospital, Johannesburg registered in the South African 
national MDR-TB program from 1
st
 January, 2007 to 31
st
 December, 2010. 
2.2 Study setting 
Sizwe Tropical Disease Hospital is situated at Edenvale and was established in 1895. In 2002, 
it became a specialised Provincial centre for the treatment of MDR-TB and in 2006, it was 
also mandated to treat XDR-TB following the emerging burden of DR-TB in South Africa. 
The hospital serves a vast majority of referred MDR/XDR-TB patients in Gauteng Province, 
who are treated as in- and out-patients.  
The hospital has a total of eight wards comprising one admission ward, five MDR-TB adult 
wards, one paediatric ward, and one XDR-TB ward. There are 244 and 22 beds for MDR-TB 
and XDR-TB patients, respectively. All MDR-TB patients in the Province are admitted for 
initiation of treatment and subsequently discharged after culture conversion (two consecutive 
negative culture results taken 30 days apart) to decentralised care. About 75% of patients 
admitted for MDR-TB treatment at Sizwe hospital are HIV positive. Planned transportation 
services that carry patients to and from the hospital are available, and there is a tight follow-
up and social welfare system to reduce the default rate. 
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2.3 Study population  
The study population comprised all TB patients aged 18 years and older registered for MDR-
TB treatment at Sizwe Tropical Disease Hospital in Johannesburg, South Africa from 1
st
 
January, 2007- 31
st
 December, 2010.  
2.4 Study sample 
A total of 1,200 records of adult patients from the electronic database of Sizwe Tropical 
Disease Hospital suspected to be MDR-TB/HIV co-infected were reviewed over a four year 
period. The following eligibility criteria were applied to ensure that the study sample was 
correctly selected (see Figure 3.1). 
2.4.1 Inclusion criteria:  
 These included patients on treatment for MDR-TB at Sizwe Tropical Disease Hospital who 
were: 
 HIV positive adults aged 18 years and older,  
 With confirmed drug susceptibility test results showing resistance to isoniazid and 
rifampicin. 
2.4.2 Exclusion criteria: 
 Patients younger than 18 years old. 
 Patients who were HIV negative. 
 Patients with no HIV test results or unknown HIV status. 
 Individuals with missing records or case notes. 
 Patients with earlier treatment dates before commencement of study. 
 Those who died within 24 hours of treatment initiation and individuals who defaulted 
just after the first visit.  
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 Patients whose drug susceptibility tests (DST) were not confirmatory of MDR-TB 
(mono/poly resistance) and whose treatment were discontinued (pan susceptible 
patients).  
 XDR-TB patients. 
2.5 Data sources and measurement  
Patients who were culture positive and confirmed to be having MDR-TB by DST or line 
probe assay (LPA) in all the sub-divisions of the National Health Service Laboratory (NHLS) 
throughout Gauteng province were referred from their clinics to Sizwe Tropical Disease 
Hospital. The NHLS performs culture and DST for DR-TB using liquid media such as 
BACTEC Mycobacterial Growth Indicator Tube (MGIT) 960 and Becton Dickinson which 
uses fluorescence quenching-based oxygen sensor for detection of mycobacterial growth.   
Referred patients were first screened at Gateway clinic to ensure that results were suggestive 
or confirmatory of MDR-TB and initial registration was done for these patients. This was 
followed by a DST for all the first and second-line anti-tuberculous agents. Weight and 
height were measured for every patient before the start of MDR-TB treatment, except where 
patients were too ill to stand for the measurements. Baseline measurements of haemoglobin 
level, electrolytes, urea and creatinine, thyroid function test, liver function test, and CD4 cell 
count were also done prior to or during treatment. 
Patients with unknown HIV status were referred to Thusong clinic for HIV counselling and 
testing. An initial rapid test was done and if reactive, a confirmatory Enzyme Linked 
Immuno-sorbent Assay (ELISA) followed. Newly diagnosed HIV patients were encouraged 
to initiate ART as soon as possible except where patients were too ill to commence treatment 
or declined initiation of ART. Prior to 2010, the WHO guideline for commencement of ART 
in patients with a confirmed diagnosis of DR-TB was based on a CD4 count of less than 350 
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cells/mm³. The guideline that followed regulated that patients be started on ART within 2-8 
weeks, irrespective of the CD4 cell count (7, 48). Patients who were diagnosed to be HIV 
positive on admission and those already on ART were also referred to Thusong clinic for 
adherence counselling, continuous ARV administration and follow-up on HIV treatment.  
The majority of the patients were started on the standardized regimen based on initial DST 
results (especially newly diagnosed MDR-TB patients); the choice for the next regimen was 
individualized based on follow-up DST results. Some patients’ regimens were modified at 
baseline based on medical history, pre-existing adverse events and co-morbidities (called 
individualised regimen at baseline in this study). Patients were first commenced on the IP 
comprising KM/AM, MFX, ETO, TDR, and PZA taken at least six days a week for at least 6 
months until after the first culture negative sputum.  
Most of the patients were transferred to their local clinics with DOTS support groups who 
continued monitoring patients’ treatment after one or two consecutive negative culture 
results. Adverse events, co-morbidities, and presence of opportunistic infections were 
managed and documented by clinicians during treatment and follow-up. Patients were given 
personal files which contained information on management at their local clinics and monthly 
sputum results for which they presented at the hospital during follow-up visits. The schedule 
for follow-up included: visits one month after discharge and subsequently 3 monthly with 
chest x-rays reviewed during each visit until the patient had completed treatment except 
where patients had other co-morbidities. Upon completion of treatment, patients were 
followed up 6 monthly for 2 years (a total of 4 visits after treatment completion) during 
which chest x-rays were done on each visits.  
15 
 
2.6 Data collection 
Part of the data for this study comprised demographic and outcome records from the National 
TB registers. The data collected were for both HIV positive and HIV negative MDR-TB 
patients. The medical case files of HIV positive patients were reviewed for socio-
demographic and clinical information not recorded on the TB register. Baseline x-rays of the 
patients were also reviewed. Data were entered into an Excel spreadsheet. Data collection 
started on the 14
th
 November, 2013 and ended on the 21
st
 February, 2014. 
2.7 Outcome variable 
 The treatment outcomes of MDR-TB included: cure, completed treatment, defaulted, failed 
treatment, transferred out, still on treatment and died.  
2.8 Exposure variables 
 The main exposure variable was receiving ART (before or after MDR-TB treatment 
initiation). Other exposure variables included the socio-demographic information like age, 
gender, employment status, race, and clinical information such as history of prior TB 
treatment, initial smear status, date of diagnosis of MDR-TB, days from diagnosis to MDR-
TB treatment start, baseline DST result, duration on ART, baseline CD4 count, weight, 
height, BMI, haemoglobin level, baseline regimen, baseline chest radiographic findings, other 
opportunistic infections occurring during the course of treatment, presence of other co-
morbidities, and adverse events.  
2.9 Definition of study variables 
2.9.1 Outcome variables 
Definitions of MDR-TB treatment outcomes according to the WHO and South African 
Department of Health Drug-resistant TB Policy Guidelines 2013 (7, 49):  
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 Cure: A patient who has converted (with 2 consecutive TB culture negative taken 30 
days apart), and has remained TB culture negative, has completed treatment and has 
been consistently culture-negative for five consecutive months in the final twelve 
months of treatment. If one positive culture is reported during that time and there is no 
concomitant clinical evidence of deterioration, a patient may still be considered cured, 
provided that this positive culture is followed by a minimum of three consecutive 
negative cultures, taken at least thirty days apart. This outcome is restricted to 
confirmed pulmonary DR-TB patients. 
 Treatment completed: A patient who has completed treatment but does not meet the 
definition for cure due to lack of bacteriologic results (i.e. less than five cultures were 
performed in the final twelve months of treatment). 
 Death: A patient who dies from any cause while on DR-TB treatment. 
 Treatment default: A patient who interrupts DR-TB treatment for two or more 
consecutive months for any reason. 
 Treatment failure: A patient who has had two or more of the five consecutive cultures 
taken in the final twelve months and are positive, or if any one of the final three 
cultures are positive. Treatment failure may be observed in patients who do not 
respond to treatment after 6 to 8 months of effective treatment. Such patients will be 
put on a different treatment regimen after receiving an outcome of failure and be 
allocated to a new treatment cohort. 
 Transfer out: A patient who has been transferred to a reporting unit in another 
province and for whom the treatment outcome is unknown. 
 Still on treatment: A patient who for any reason is still on treatment at the time of 
submission of treatment outcome report. 
  Treatment success: The sum of cured and treatment completed. 
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2.9.2 Exposure variables 
2.9.2.1 Socio-demographic variables 
 Age: age of patient in years at time of start of MDR-TB treatment, 
 Gender: gender of patient (male or female), 
 Employment status: Employed or unemployed at initiation of MDR-TB treatment, 
 Race: Black, White, Coloured, and Indian. 
2.9.2.2 Clinical information 
 Clinical characteristics of the cohort such as initial smear status (positive, negative, or 
not available), history of prior TB treatment also known as categories of MDR-TB 
(Category I: new patient who has received no anti-TB treatment for TB, MDR- or 
XDR-TB or received less than one month of anti-TB drug; category II: previously 
treated for one month or more with first-line drugs; category III: Previously treated 
for one month or more for TB or DR-TB with one or more of second-line drugs), 
baseline regimen (standardized: at least on 5 recommended drugs at baseline, 
individualised: modified regimen based on co-morbid conditions and adverse events 
with some drugs delayed), date of report of MDR-TB, date of start of MDR-TB 
treatment, duration on MDR-TB treatment, duration on ART (days), and the use of 
co-trimoxazole prophylaxis.  
 Other variables included weight (Kilograms), height (meters), BMI-Kg/m² (severely 
underweight: <16, underweight: ≥16-18.49, normal: 18.5-24.99, overweight: 25-29.99 
and obese: ≥30), baseline CD4 cell count (cells/mm³), haemoglobin level (g/dl), 
baseline chest radiographic findings (infiltrative lesions, cavitary, fibrosis or pleural 
effusion), presence of other opportunistic infections (such as oral or vaginal or 
oesophageal candidiasis, recurrent oral or genital Herpes simplex virus infection 
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(HSV), Pneumocystis Jirovecii Pneumonia (PCP), Herpes zoster infection, 
Cryptococcal infection, Cytomegalovirus (CMV) infection, cervical dysplasia or 
cancer, Kaposi sarcoma, HIV-associated nephropathy (HIVAN)). 
 And finally co-morbidities (such as diabetes mellitus (DM), hypertension, 
cerebrovascular disease, heart failure, chronic kidney disease, chronic liver disease, 
asthma and chronic obstructive airway disease, cardiomyopathies and arrhythmias, 
deep venous thrombosis, sepsis, pancreatic disorders, cancers), and adverse events 
(ototoxicity, nephrotoxicity, hepatotoxicity, joint pains, severe gastrointestinal 
symptoms like nausea and vomiting requiring treatment, visual changes and 
conjunctivitis, psychosis, depression, peripheral neuropathy, hyperuricemia, 
hypothyroidism and gynaecomastia). 
2.10.0 Data management  
 Data were entered into an Excel spread sheet separately for all the 4 years of the study. 
Inconsistencies were verified from case records and corrections were effected. The data were 
then transferred into STATA 12 for analysis. The data were cleaned by excluding individual 
records that did not meet the eligibility criteria (see Figure 3.1: flowchart); and missing data 
were checked for each variable.  Continuous variables were recoded into categories for 
example age into age groups (≤45 years and >45 years), BMI (<16 kg/m² as severely 
underweight, ≥16-18.49 kg/m² as underweight, 18.50-24.99 kg/m² as normal, 25-29.99 kg/m² 
as overweight, ≥30 kg/m²  as obese), CD4 (<150 cells/mm³, ≥150-349, ≥350), haemoglobin 
level (normal, mild, moderate and severe anaemia levels) to avoid residual confounding 
which may exist when such data are modelled as continuous.  
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New variables which were important for analyses were generated from existing data. The 
data for the four years were then appended to create a composite dataset which was used in 
the final analyses. Incomplete dates (day and months) were imputed for when patients 
experienced an outcome and date of ART initiation using the 15
th
 of every month as day and 
mid-year (June) as months where only the year was recorded. Person times (treatment 
duration) were calculated from the dates of MDR-TB treatment initiation and outcomes. The 
variable ART duration was created from dates of commencement of ART and date of MDR-
TB  treatment initiation and those who commenced ART after MDR-TB treatment were 
categorized into immediate (≤28 days), early (29-56 days) and late (≥57 days) (22). 
Categorized variables with sparse numbers such as race were merged into black and others 
(white, coloured and Asian), and overweight and obese BMI were also merged into one 
category. Continuous data were checked for normality formally using the Shapiro-Wilk’s test 
and graphically using histograms and normal quantile plots; as well as for skewness and 
kurtosis.  
2.11.0 Data analysis 
2.11.1 Descriptive and inferential statistics 
Baseline demographic and clinical characteristics of the patients were described numerically 
using frequency distribution tables and graphically using bar or pie charts, and spine/tab plots 
for categorical data. Continuous data which followed a normal distribution were described 
numerically using means and standard deviations and median and interquartile ranges were 
used for non-normal and skewed data. Histograms were used to display continuous variables. 
 Baseline characteristics, clinical information and outcomes were compared between the two 
ART exposure groups excluding individuals who were not on ART or whose ART 
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information were not available. Pearson’s chi-square test was used to compare categorical 
variables across the main exposure groups and Fisher’s exact test was used where there were 
sparse data of ≤5 in 20% of the cells. Continuous variables which followed a normal 
distribution were compared using the student t-test and the Wilcoxon Rank-sum test used for 
non-normal/skewed data. All analyses were performed excluding missing data. 
2.11.2 Assessment of effect modification and confounding 
Stratified analyses were done for the three important outcomes: died, cure and failure with 
the main exposure and each of the covariates to check for effect modification and 
confounding. Variables with a significant Mantel-Haenszel’s homogeneity p-value of <0.05 
were considered as effect modifiers and those with greater than 10% difference between the 
crude and adjusted estimates were considered as confounders. These were considered for 
inclusion during the model building process of the final multivariable model. 
2.11.3 Univariable and multivariable analyses 
Univariable logistic regression analyses were done for all variables to determine the 
predictors of mortality, and cure. The low prevalence of patients, who failed treatment 
compared with the total study sample, necessitated the use of univariable Poisson regression 
to determine predictors of treatment failure. Statistically significant variables at a p-value of 
<0.1 and a priori biologically plausible covariates were considered important factors to be 
included in the multivariable regression analyses.  
Multivariable logistic regression models were used to assess the effect of ART and other 
predictors of mortality and cure; while multivariable Poisson models were used for predictors 
of failure. A stepwise model building was done starting with the main exposure (ART timing) 
and subsequently including variables that were significant during the univariable analyses 
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while assessing the change in estimates. Variables were modelled either as categorical or 
continuous and interaction terms were included. Models were compared using the likelihood 
ratio test (lrtest), and Akaike International Criterion (AIC) to determine the best approach of 
including such variable or interaction term in the final multivariable model. Models with 
significant lrtest p-values or lower AIC were considered better than those with insignificant 
p-values or higher AIC. Potential confounders were adjusted for in the final multivariable 
models. Odds ratios were calculated for logistic models and incidence rate ratios (IRR) for 
Poisson models at 95% confidence interval and alpha level of <0.05.  
Two models were built for mortality during the final multivariable analyses. Model 1: did not 
consider co-morbidity as an effect modifier; while for model 2 an interaction term was fit 
between the timing of ART initiation and presence of co-morbidity. There was no statistically 
significant interaction term between the timing of ART initiation and co-morbidity in the 
presence of other covariates; hence this model was dropped. Three models were also built for 
cure. Model one did not consider gender as an effect modifier.  For model 2, an interaction 
term was fit between timing of ART and gender; while for model 3 an interaction term was 
fit with timing of ART and age groups, but this was not statistically significant. Model two 
was considered as the final and most parsimonious because there was a statistically 
significant interaction term between timing of ART regimen and gender. The final 
multivariable Poisson model for failure was specified using the vce-option (which uses the 
robust or sandwich estimator of variance) to obtain robust standard errors  and to control for 
mild violation of the Poisson distribution assumptions, and these were comparable with 
results from the zero-inflated and negative binomial Poisson models. Time to event analysis 
was considered as a robust method for analysing this data, but the disparity in follow-up 
duration for the three major outcomes when others were considered to be censored did not 
allow the statistical method to fit the data well. 
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2.11.4 Model diagnostics 
Model specification error was assessed using the link test command to ascertain that the 
linear predicted value and linear predicted value squared of the final models were correctly 
specified. A significant linear predictive value squared denotes a significant linktest and this 
depicts a specification error. The Box-Tidwell model (using the boxtid command) which 
transforms a predictor using power and exponential transformations were also used to find 
the best power for model fit based on maximum likelihood estimates. An insignificant p-
value for the test of non-linearity depicts that the predictors be modelled as linear terms. The 
Hosmer-Lemeshow goodness-of-fit test was done for each model to assess any evidence of 
lack of fit. Multi-collinearity was assessed using the variance inflation factor (VIF) and 
tolerance level. Variables with VIF greater than 10 and tolerance level less than 0.1 were 
considered to be of perfect collinearity.  Influential observations were assessed using the 
Pearson, deviance residuals and the Pregibon (hat diagonal) leverage.  Sensitivity analysis 
were done for different models where observations with large leverage and residuals were 
removed and compared with original models with intact observations to assess for significant 
changes in estimates. All statistical analysis were done using STATA version 12.  
2.12.0 Ethical considerations 
The study was approved by the University of the Witwatersrand Human Research Ethics 
Committee (Medical) in September, 2013. Ethical approval certificate is attached (see 
Appendix 1). Permission to review medical records was also granted by the Chief Executive 
Officer of Sizwe Tropical Disease Hospital (see Appendix 3). 
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CHAPTER 3: RESULTS 
In this chapter the results are presented based on the study objectives and analysis plan. The 
demographic, clinical characteristics and outcomes of MDR-TB are reported. Predictors of 
mortality, cure and failure are summarised based on results from univariable and 
multivariable analyses. 
3.1 Baseline characteristics 
A total of 2,005 MDR-TB patients were admitted from 1st January, 2007 to 31st December, 
2010. Of these, 1,200 adult patients had HIV positive status recorded on the database; 12 
patients were excluded because laboratory records confirmed HIV negative status, and 2 
patients had HIV status unknown during the course of treatment. In addition, 31 patients were 
excluded because their case files were missing, 7 patients were excluded on account of 
misdiagnosis (mono and poly-resistance); 4 patients had treatment start date prior to 
commencement of the study, 3 patients died within 24 hours of commencement of treatment 
and 2 treatment defaulters died after the first visit. Furthermore, 1 patient was excluded on 
account of XDR-TB and 1 was an infant aged 6 months. Therefore out of the 1,200 patients 
with data on HIV positive status, 1,137 patients met the eligibility criteria and were included 
in the analyses (see Figure 3.1). 
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Figure 3.1: Exclusion and inclusion criteria flowchart of the cohort. 
 
430 MDR-TB patients in 2007 
501 MDR-TB patients in 2008 
506 MDR-TB patients in 2009 
568 MDR-TB patients in 2010 
1200 MDR-TB adult patients from the data base suspected to be 
HIV positive adults 
31 patients with no records 
12 HIV Negative and 2 Unknown HIV statuses 
4 Wrong treatment dates (earlier than study duration) 
7 Not MDR-TB (5 Misdiagnosis, 2 Mono and poly resistance) 
1 XDR, 1 six months old 
3 Died within 24hours of start of treatment   
 2 defaulted and died after first visit 
1137 patients met the eligibility 
173 Not on ART and 17 ART statuses not available: 190 
excluded 
947 patients on ART 
545 patients on ART Prior 
to MDR-TB treatment 
402 patients on ART After 
commencement of MDR-
TB treatment 
233, 240, 158, and 174 records of patients <18years, HIV 
negative and unknown HIV status excluded in 2007, 2008, 
2009 and 2010 respectively.  
78 Immediate ART initiation 
118 Early ART initiation 
203 Late ART initiation 
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Tables 3.1.1 and 3.1.2 present the baseline characteristics of the study sample. The median 
age of patients was 36 years with an interquartile range (IQR) of 31-43 years and 50.2 % 
(572) were females. A total of 98.9% (1124) of the patients were blacks with 38.6% (439) 
living within the City of Johannesburg Metropolitan district. Of all patients, 72.4% (823) 
were unemployed. About 83% (940) of the patients had PTB, while 17.3% (197) had 
pulmonary and/or EPTB. Patients with category I (New) MDR-TB constituted 22.9% (260), 
while 57.6% (655) and 19.5% (222) of the patients were in categories II and III respectively 
as defined in the methods section. 58% of the patients had their pre-treatment smear results as 
positive, 30% had it as negative and 11% had no smear results. The median duration from 
diagnosis and report of MDR-TB infection by the NHLS laboratory across the province to the 
start of MDR-TB treatment was 10 days with IQR of 4-21 days. The mean haemoglobin was 
11.1 g/dl with a standard deviation (SD) of 2.3 g/dl and the median CD4 count was 167.5 
cells/mm³with an IQR of 79-288 cells/mm³. 
Table 3.1.1: Baseline Demographic characteristics of HIV positive adults on MDR-TB 
treatment at Sizwe Tropical Disease Hospital. 
Factors N (%) (N = 1137) 
Age 36 (31-43)** 
Gender   
Male 566 (49.8) 
Female 571 (50.2) 
District   
Westrand 137 (12.1) 
Sedibeng 82 (7.2) 
Tswhane 202 (17.8) 
Ekhurhuleni 267 (23.5) 
City of Johannesburg 439 (38.6) 
Metsweding 10 (0.9) 
Race 
 Black 1124 (98.9) 
Others 13 (1.1 ) 
Employment status 
 Employed 314 (27.6) 
Unemployed 823 (72.4) 
N - Number in each group; % - Percentages; * *Median and Interquartile range. 
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Table 3.1.2: Baseline clinical characteristics of HIV positive adults on MDR-TB 
treatment at Sizwe Tropical Disease Hospital. 
Factors N (%) (N = 1137) 
Categories of MDR-TB 
 Category I (New) 260 (22.9) 
Category II 655 (57.6) 
Category III 222 (19.5) 
Pre-treatment smear status 
 Negative 345 (30.3) 
Positive 666 (58.6) 
Not available 126 (11.1) 
Site of TB   
Pulmonary 940 (82.7) 
Extra-Pulmonary + Pulmonary 197 (17.3) 
Treatment outcomes 
 Still on treatment 13 (1.1) 
Transfer out 52 (4.6) 
Treatment Defaulted 254 (22.3) 
Treatment Completed 188 (16.5) 
Cure 339 (29.8) 
Failure 33 (2.9) 
Died 258 (22.7) 
Receiving ART 
 After 402 (35.4) 
Prior 545 (47.9) 
No 173 (15.2) 
Not available 17 (1.5) 
ART duration 
 Prior 491 (55.2) 
Immediate (≤28days) 78 (8.8) 
Early (29-56days) 118 (13.2) 
Delayed (≥57days) 203 (22.8) 
Weight (N = 1087) 51.3 (45.0-58.7)** 
Weight categories (N = 1087) 
 ≤45kg 275 (25.3) 
45.1-<60kg 562 (51.7) 
≥60kg 250 (23.0) 
BMI categories (kg/m²)   
Severely Underweight (<16) 123 (10.8) 
Underweight (≥16-18.49) 276 (24.3) 
Normal (≥18.5-24.99) 435 (38.3) 
Overweight/obese (≥25) 84 (7.4) 
Missing 219 (19.3) 
Co-trimoxazole Prophylaxis 
 No 136 (12.0) 
Yes 829 (72.9) 
Missing 172 (15.1) 
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CD4 cell count (mls/mm³) 167.5 (79-288)** 
CD4 Categories   
<150 485 (42.7) 
150-349 398 (35.0) 
≥350 193 (17.0) 
Missing 61 (5.4) 
Haemoglobin (g/dl) 11.1 (2.3)* 
Haemoglobin categories (g/dl)  
 Severe (≤7) 44 (3.9) 
Moderate (7.1-9.99) 300 (26.4) 
Mild (10-10.99) 175 (15.4) 
Normal (≥11) 598 (52.6) 
Missing 20 (1.8) 
Outcome duration (days) 669 (236-880)** 
Duration from report of MDR to start of treatment 
(days) 
10 (4-21)** 
Infiltrative changes on chest radiograph 
 No 56 (5.1) 
Yes  1,054 ( 94.9) 
Cavitary change on chest radiograph 
 No 637 (57.4)  
Yes 473 (42.6) 
Fibrotic changes on chest radiograph 
 No 154 (13.9) 
Yes 955 (86.1) 
Pleural effusion on chest radiograph 
 No 1,021 (92.1) 
Yes  88 (7.9) 
Other Opportunistic Infections 
 No 752 (66.1) 
Yes 381 (35.5) 
Missing 4 (0.4) 
Comorbidity 
 No 965 (84.9) 
Yes 150 (13.2) 
Missing 22 (1.9) 
Adverse events 
 No 657 (57.8) 
Yes 459 (40.4) 
Missing 21 (1.9) 
Regimen type at baseline 
 Standardised 792 (69.7) 
Individualised 328 (28.9) 
Missing 17 (1.5) 
N - Number in each group; % - Percentages; * *Median and Interquartile ranges; *Mean and standard 
deviation 
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Out of the 1,137 records included in the analysis, 1.1% (13) of the patients were still on 
treatment, 4.6% (52) were transferred out to other centres, 22.3% (254) defaulted treatment, 
16.5% (188) completed treatment, 29.8% (339) were cured, 2.9% (33) failed treatment and 
22.7% (258) died while on treatment (see Figure 3.1). Patients who commenced ART prior to 
commencement of MDR-TB treatment made up 47.9% of the entire population while 35.4% 
(402) started ART after commencement of MDR-TB treatment (see Appendix 5 for Figure 
3.2). Of the 402 patients who started ART after initiating MDR-TB treatment, 8.8% (78) 
were commenced on ART within 28 days of initiating MDR-TB treatment; 13.3% (118) were 
initiated on ART within 29-56 days after commencing MDR-TB treatment and 22.8% (203) 
commenced ART after 57 days following MDR-TB treatment start. See Appendix 6 for 
Figure 3.3. 
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Figure 3.2: Outcomes of MDR-TB treatments in HIV positive adults at Sizwe Tropical 
Disease Hospital from 1
st
 January, 2007 to 31
st
 December, 2010. S “Still on treatment”; TO 
“Transferred-out”; TD “Treatment Defaulted”; TC “Treatment Completed”; and TF 
“Treatment Failure”. 
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3.2 Inferential statistics 
There was a statistically significant difference in the categories of MDR-TB among patients 
who started ART before and after initiation of MDR-TB treatment (p = 0.026), see Table 
3.2.2. The proportion of new MDR-TB (category I) patients was higher among patients 
started on ART after initiating MDR-TB treatment (26.3% vs. 19.6); while those in categories 
II (58.7% vs. 62.0%) and III (14.7% vs. 18.4%) were similar between those started on ART 
after  and before MDR-TB treatment initiation, respectively. EPTB/PTB was significantly 
higher among patients commenced on ART before compared with those started on ART after 
MDR-TB treatment initiation (20.73% vs. 13.93%, (p = 0.007)).  
Compared with those started on ART after MDR-TB treatment initiation, more patients 
started on ART prior to commencement of MDR-TB treatment were on Co-trimoxazole 
prophylaxis (95.63% vs. 90.27%) and this was statistically significant (p = 0.003). The mean 
haemoglobin was significantly higher among patients who started ART prior to (11.32 (SD = 
2.38)) compared with patients who commenced ART after MDR-TB treatment initiation 
(10.8 (SD = 2.2)), p = 0.001. This significant difference was also noticed among the different 
categories of haemoglobin (p = 0.009).  
The presence of other non-TB opportunistic infections was higher among patients started on 
ART after commencement of MDR-TB treatment (42.9% vs. 26.6%, (p <0.001)) than in 
those on ART prior to commencement of MDR-TB treatment.  A higher proportion of 
patients initiated on ART before commencement of MDR-TB treatment were on modified 
individualised regimen at baseline (31.5% vs. 24.9%, (p = 0.029)). The person time was 
significantly different amongst patients started on ART before and after MDR-TB treatment 
initiation with median duration of 251 days (IQR = 90-725) and 720 days (IQR = 330-945) 
for both groups respectively, (p = 0.029). See Table 3.2.2. 
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Table 3.2.2: Bivariate analysis of clinical characteristics of MDR-TB HIV co-infected 
adults based on exposure to ART before or after commencement of MDR-TB 
treatment. 
Factors 
ART prior to 
commencement of 
MDR-TB 
treatment 
ART after 
commencement 
of MDR-TB 
treatment Test Statistic p-value 
  N (%) (N= 545) N (%) (N= 402)     
Categories of MDR-TB         
Category I (New) 107 (19.6) 107 (26.6) Chi = 7.270 0.026* 
Category II 338 (62.0) 236 (58.7)     
Category III 100 (18.4) 59 (14.7)     
Pre-treatment smear status         
Negative 166 (30.5) 134 (33.3) Chi = 1.038 0.595 
Positive  317 (58.2) 221 (55.0)     
Not available 62 (11.4) 47 (11.7)     
Site of TB         
Pulmonary 432 (79.3) 346 (86.1) Chi = 7.304 0.007* 
Extra-Pulmonary + Pulmonary 113 (20.7) 56 (13.9)     
Treatment outcomes         
Still on treatment 5 (0.9) 8 (2.0) Chi = 10.770 0.096 
Transfer out 26 (4.8) 18 (4.5)     
Treatment Defaulted 105 (19.3) 101 (25.1)     
Treatment Completed 92 (16.9) 71 (17.7)     
Cure 182 (33.4) 130 (32.3)     
Failure 16 (2.9) 12 (3.0)     
Died 119 (21.8) 62 (15.4)     
Combining cure and TC as Successful 
treatment         
Still on treatment 5 (0.9) 8 (2.0) Chi = 10.614 0.060 
Transfer out 26 (4.8) 18 (4.5)     
Treatment Defaulted 105 (19.3) 101 (25.1)     
Successful Treatment 274 (50.3) 201 (50.0)     
Failure 16 (2.9) 12 (3.0)     
Died 119 (21.8) 62 (15.4)     
Weight (Kg) 51.0 (45-59)** 51.2 (45-58)**  z = -0.249 0.803 
Weight categories         
≤45kg 134 (25.9) 106 (26.5) Chi = 0.071 0.965 
45.1-<60kg 263 (50.8) 203 (50.8)     
≥60kg 121 (23.3) 91 (22.7)     
BMI categories (Kg/ m²)         
Severely Underweight (<16) 68 (15.4) 41 (11.4) Chi =  4.963  0.174 
Underweight (≥16-18.49)  130 (29.4) 111 (31.0)     
Normal (≥18.5-24.99) 195 (44.1) 176 (49.2)     
32 
 
Overweight/ obese (25-29.99) 49 (11.1) 30 (8.4)     
Co-trimoxazole Prophylaxis         
No 21 (4.4) 32 (9.7) Chi = 9.131 0.003* 
Yes 459 (95.6) 297(90.3)     
CD4 cell count (mls/mm³) 160.5 (89-270)** 156 (66-257)**  z = -1.309 0.1906 
CD4 Categories (mls/mm³)         
<150 241 (46.5) 187 (48.1) Chi = 2.434 0.296 
150-349 209 (40.4) 140 (36.0)     
≥350 68 (13.1) 62 (15.9)     
Haemoglobin (g/dl) 11.3 (2.4)* 10.8( 2.2)* t =  -3.246 0.0012*  
Haemoglobin (g/dl)          
Severe Anaemia (<7.0) 24 (4.5) 13 (3.3) Chi = 11.677 0.009*  
Moderate Anaemia (7.0-9.9) 120 (22.3) 123 (31.0)     
Mild Anaemia (10-10.99) 85 (15.8) 70 (17.7)     
Normal (≥11) 308 (57.4) 190 (48.0)     
Outcome duration or Person time (days) 251 (90- 725)** 720 (330-945)** z =  2.188 0.0286*  
Duration from report of MDR to start of 
treatment (days) 11 (5-22)** 10 (6-21)**  z = -0.099 0.921  
Infiltrative changes on chest radiograph         
No 24 (4.5)  11 (2.8) Chi = 1.806 0.179   
Yes 513 (95.5) 385 (97.2)     
Cavitary change on chest radiograph         
No 315 (58.7) 237 (59.8) Chi =  0.133 0.715   
Yes 222 (41.3) 159 (40.2)     
Fibrotic changes on chest radiograph         
No 77 (14.3) 58 (14.7) Chi = 0.0218 0.883 
Yes 460 (85.7) 337 (85.3)     
Pleural effusion on chest radiograph         
No 491 (91.4) 364 (92.2)  Chi = 0.155 0.694 
Yes 46 (8.6) 31 (7.8)     
Other Opportunistic Infections         
No 399 (73.4) 228 (57.1) Chi = 27.121 <0.001* 
Yes 145 (26.6) 171 (42.9)     
Comorbidity         
No 461 (85.8) 345 (88.0) Chi = 0.923 0.337 
Yes 76 (14.2) 47 (12.0)     
Adverse events         
No 295 (54.8) 239 (61.1) Chi = 3.669 0.055 
Yes 243 (45.2) 152 (38.9)     
Regimen type at baseline         
Standardised 370 (68.5) 295 (75.1) Chi = 4.759 0.029* 
Individualised 170 (31.5) 98 (24.9)     
N - Total number in each group; % - Column percentages; Numbers may not add-up to total because of 
missing variables; *Significant p-value, Mean and Standard Deviation;  
**Median and Inter-quartile ranges.   
Test statistic based on t-test, chi-square and Wilcoxon Rank-sum test. 
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3.3 Outcomes of MDR-TB by ART treatment groups 
Treatment outcomes were not significantly different between patients on ART before and 
after commencement of MDR-TB treatment (p = 0.096), see Table 3.2.3. When the analysis 
was restricted to patients who died, the proportion of mortality was higher for those on ART 
prior to commencement of MDR-TB treatment (21.8% vs. 15.4%, (p = 0.013)). See 
Appendix 7 for Figure 3.4. 
Table 3.2.3: Bivariate analysis of outcomes of MDR-TB in HIV co-infected adults based 
on commencement of ART prior to or after MDR-TB treatment initiation.   
Factors 
ART Prior to 
commencement 
of MDR-TB 
treatment 
ART After 
commencement 
of MDR-TB 
treatment Test Statistic p-value 
  N (%)   N (%)       
Final Outcomes         
Still on treatment 5 (0.9) 8 (2.0) Chi = 10.771 0.096 
Transferred out 26 (4.8) 18 (4.5)     
Treatment Defaulted 105 (19.3) 101 (25.1)     
Treatment Completed 92 (16.9) 71 (17.7)     
Cure 182 (33.4) 130 (32.3)     
Failure 16 (2.9) 12 (3.0)     
Died 119 (21.8) 62 (15.4)     
Died         
No 426 (78.2) 340 (84.6) Chi = 6.153 0.013* 
Yes 119 (21.8) 62 (15.4)     
Cure         
No 363 (66.6) 272 (67.7) Chi =  0.117 0.733 
Yes 182 (33.4) 130 (32.3)     
Failure         
No 529 (97.1) 390 (97.0) Chi = 0.002 0.965 
Yes 16 (2.9) 12 (3.0)     
Total 545 402     
N - Total number in each group; % - Column percentages; Test statistic = Chi-square test.  
*Significant p-value. 
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3.4 Assessment of effect modification and confounding 
3.4.1 Mortality 
In the stratified analyses for mortality, the presence of co-morbidities during MDR-TB 
treatment modified the relationship between timing of ART initiation and mortality (Mantel-
Haenszel homogeneity p-value of 0.019). Haemoglobin confounded the relationship between 
the use of ART prior to or after commencement of MDR-TB treatment by 17.7%; while the 
categories of CD4 cell count, BMI and the presence of other opportunistic infections 
confounded the relationship by 12.1%, 18.6%, and 21.9%, respectively.  
3.4.2 Cure  
Gender was an effect modifier in the relationship between timing of ART initiation and cure 
(p = 0.008) and so was age-group (p = 0.013).  
3.4.3 Failure 
The use of Co-trimoxazole prophylaxis during MDR-TB treatment confounded the 
relationship between the use of ART before or after commencement of MDR-TB treatment 
and failure by 14.0%. 
3.5 Predictors of mortality 
3.5.1 Univariable logistic regression models 
Significant predictors of mortality (Table 3.3) were being unemployed, patients started on 
ART before commencement of MDR-TB treatment, being severely underweight and 
underweight, CD4 <150 cells/mm³, low haemoglobin, the presence of other opportunistic 
infections, co-morbidities, adverse-events, and PTB and/or EPTB. 
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3.5.1.1 Socio-demographic factors 
 Patients who were unemployed were 1.6 times more likely to die compared with 
patients who were employed (OR: 1.64; 95% CI: 1.12-2.44; p = 0.014). 
3.5.1.2 Clinical factors 
Patients who used ART before commencement of MDR-TB treatment were more likely to 
die compared with those on ART after starting MDR-TB treatment (OR: 1.53; 95% CI: 1.09-
2.15; p = 0.014). Patients who were severely underweight were 4.6 times more likely to die 
(OR: 4.61; 95% CI: 2.77-7.68; p <0.001) and those who were underweight were twice as 
likely to die (OR: 2.33; 95% CI: 1.49-3.65; p <0.001) when both were compared with 
patients with normal BMI. Those with CD4 count <150 cells/m³ were nearly three time as 
likely to die compared with patients with CD4 count >350 cells/m³ (OR: 2.88; 95% CI: 1.62-
5.14; p <0.001). For every unit increase in haemoglobin, there was a 0.8 decrease in odds of 
mortality (OR: 0.76; 95% CI: 0.70-0.82; p <0.001) and this was reflected in the different 
categories of haemoglobin. Those with other opportunistic infections were 2.5 times more 
likely to die compared with patients with no other opportunistic infections (OR: 2.54; 95% 
CI: 1.82-5.97; p <0.001). 
Patients with Co-morbidities were nearly 4 times more likely to die compared with patients 
without other co-morbidities (OR: 3.97; 95%CI: 2.64-5.97; p <0.001). Individuals with the 
presence of adverse events were 1.5 times more likely to die compared with those with no 
adverse events during treatment (OR: 1.45; 95% CI: 1.04-2.02; p = 0.028). Compared with 
standardised regimen at baseline, patients on individualised regimen were 1.6 times more 
likely to die (OR: 1.55; 95% CI: 1.10-2.19; p = 0.013). Patients with  EPTB with/or without 
PTB were 1.4 times more likely to die compared with patients with PTB only (OR: 1.40; 95% 
CI: 0.94-2.09; p = 0.098); while patients previously treated with second-line agents (category 
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III) were less-likely to die compared with patients not previously treated for TB or MDR-TB 
(OR: 0.59; 95% CI: 0.33-1.05; p = 0.073). 
3.5.2 Multivariable logistic model 
3.5.2.1 Clinical factors 
Patients who received ART prior to commencement of MDR-TB treatment were 1.8 times 
more likely to die compared with those who commenced ART after initiation of MDR-TB 
treatment (OR: 1.76; 95% CI:1.07-2.91; p = 0.026), adjusting for confounders such as BMI, 
haemoglobin, CD4 cell count and the presence of other opportunistic infections. Compared 
with normal BMI, those who were severely underweight (OR: 3.46; 95% CI: 1.77-6.77; p 
<0.001) and underweight (OR: 2.31; 95% CI: 1.28-4.15; p = 0.005) were more likely to die. 
See Table 3.3. 
Patients with the presence of cavitary lesions on baseline chest x-ray were 1.8 times more 
likely to die (OR: 1.83; 95% CI: 1.13-2.96; p = 0.014) compared with patients without 
cavitary lesions. Those with the presence of other opportunistic infections had a higher odds 
of mortality compared with patients without other opportunistic infections (OR: 1.84; 95% 
CI: 1.13-3.00; p = 0.014). Compared with patients without co-morbidity, individuals with co-
morbidities were 2.5 times more likely to die (OR: 2.51; 95% CI: 1.34-4.68; p = 0.004). 
There was a trend with factors such as haemoglobin (OR: 0.89; 95% CI [0.79-1.00]; p = 
0.060) with reduced odds of mortality for every unit increase in haemoglobin; although this 
was not statistically significant. There was no statistically significant interaction between 
timing of ART initiation and co-morbidity (p = 0.229) with an lrtest p = 0.220; hence the 
model with the interaction term was dropped. There were no highly correlated variables and 
no evidence of lack of fitness of the final model as the Hosmer-Lemeshow goodness-of-fit p-
value was 0.449. The model was correctly specified (specification error p = 0.529).  The 
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variable haemoglobin was correctly modelled as a linear term (non-linearity p = 0.200), and 
the VIF and tolerance levels were all within normal limits. Removal of observations with 
large Pearson and deviance residuals as well as influential points did not significantly change 
the estimates from the previous models. 
Table 3.3: Predictors of mortality in HIV positive adults on MDR-TB treatment at 
Sizwe Tropical Disease Hospital, Johannesburg. 
   ªUnivariable Analysis  ᵇMultivariable Analysis  
Factor  
Unadjusted 
OR 
Confidence 
interval 
p-value 
Adjusted 
OR 
Confidence 
interval 
p-value 
ART regimen             
After 1.00 Ref   1.00 Ref   
Prior 1.53 1.09-2.15 0.014* 1.76 1.07-2.91 0.026* 
Age 1.01 0.99-1.03 0.481       
Gender             
Female 1.00 Ref   1.00 Ref   
Male 1.08 0.78-1.49 0.661 1.52  0.91-2.55 0.110 
District             
Westrand 1.00 Ref         
Sedibeng 0.87 0.39-1.95 0.740       
Tswhane 1.10 0.60-2.03 0.753       
Ekhurhuleni 0.94 0.51-1.70 0.826       
City of Johannesburg 1.24 0.72-2.14 0.440       
Metsweding 1.53 0.29-8.16 0.616       
Race             
Other 1.00 Ref         
Black 0.78 0.21-2.88 0.715       
Employment status             
Employed 1.00 Ref         
Unemployed 1.64 1.12-2.44 0.014*       
Categories of MDR-TB             
Category I (New) 1.00 Ref         
Category II 1.07 0.72-1.59 0.732       
Category III  0.59 0.33-1.05 0.073       
Pre-treatment smear status             
Negative 1.00 Ref         
Positive 1.34 0.93-1.92 0.113       
Not available 0.54 0.27-1.07 0.076       
Site of TB             
Pulmonary 1.00 Ref         
Extra-Pulmonary + Pulmonary 1.40 0.94-2.09 0.098       
BMI categories (kg/m²)             
Severely Underweight (<16) 4.61 2.77-7.68 <0.001* 3.46 1.77-6.77 <0.001* 
Underweight (≥16-18.49) 2.33 1.49-3.65 <0.001* 2.31 1.28-4.15 0.005* 
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Normal (≥18.5-24.99) 1.00 Ref   1.00 Ref   
Overweight/ obese (25-29.99) 1.20 0.57-2.51 0.630 2.28 0.94-5.50 0.067 
Co-trimoxazole Prophylaxis             
No 1.00 Ref   1.00 Ref   
Yes 1.33 0.62-2.89 0.464 1.27 0.47-3.48 0.639 
CD4 Categories (mls/mm³)             
<150 2.88 1.62-5.14 <0.001* 1.62 0.77-3.48 0.213 
150-349 0.91 0.48-1.72 0.770 0.64 0.28-1.43 0.275 
≥350 1.00 Ref   1.00 Ref   
Haemoglobin (g/dl) 0.76 0.70-0.82 <0.001* 0.89 0.79-1.00 0.060 
Infiltrative changes on chest 
radiograph             
No 1.00 Ref         
Yes 0.74 0.33-1.67 0.470       
Cavitary changes on chest 
radiograph             
No 1.00 Ref   1.00 Ref   
Yes 1.25 0.89-1.74 0.191 1.83 1.13-2.96 0.014* 
Fibrotic changes on chest 
radiograph             
No 1.00 Ref         
Yes 1.17 0.71-1.91 0.527       
Other Opportunistic Infections             
No 1.00 Ref   1.00 Ref   
Yes 2.54 1.82-3.55 <0.001* 1.84 1.13-3.00 0.014* 
Comorbidity             
No 1.00 Ref   1.00 Ref   
Yes 3.97 2.64-5.97 <0.001* 2.51 1.34-4.68 0.004* 
Adverse events             
No 1.00 Ref   1.00 Ref   
Yes 1.45 1.04-2.02 0.028* 1.07 0.67-1.73 0.771 
Regimen type at baseline             
Standardised 1.00 Ref         
Individualised 1.55 1.10-2.19 0.013*       
*Significant p-values; OR: Odds ratios; Hosmer-Lemeshow Goodness-of-fit test p =  0.4489;  
 Model specification test p = 0.529; 
ᵃUnadjusted model; ᵇAdjusted for BMI, haemoglobin, CD4, and other opportunistic infections. 
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3.6 Predictors of cure 
3.6.1 Univariable analyses 
The following factors were predictors of cure during the univariable analyses (see Table 3.4): 
3.6.1.1 Socio-demographic factors 
Patients in the age group 46-76 years were 1.6 times more likely to be cured compared with 
those in the younger age group (OR: 1.59; 95% CI: 1.13-2.45; p = 0.008). Patients from 
Johannesburg Metropolitan district (OR: 0.63; 95% CI: 0.41-0.99; p = 0.043) and 
Ekhurhuleni district (OR: 0.63; 95% CI: 0.39-1.01; p = 0.056) were less likely to be cured 
compared with patients from the Westrand district. Unemployed patients were 0.8 times less 
likely to be cured compared with those who were employed (OR: 0.75; 95% CI: 0.56-1.02; p 
= 0.063). 
3.6.1.2 Clinical factors 
Compared with patients with CD4 count “<150 cells/m³”, those with CD4 cell counts 
between “150-349 cells/m³” (OR: 1.42; 95% CI: 1.05-1.92; p = 0.023) and “≥350 cells/m³” 
(OR: 1.58; 95% CI: 1.05-2.38; p = 0.028) were more likely to be cured. Patients with the 
presence of other opportunistic infections were 0.7 times less likely to be cured compared 
with patients without other opportunistic infections (OR: 0.66; 95% CI: 0.49-0.89; p = 
0.007). The presence of other co-morbidities was associated with lower likelihood of cure 
compared with absence of other co-morbidities (OR: 0.59; 95% CI: 0.38-0.91; p = 0.018). 
Individualised regimen at baseline compared with standardized regimen was associated with 
lower likelihood of cure (OR: 0.67; 95% CI: 0.49-0.91; p = 0.012).  
Patients with infiltrative changes on chest radiograph were 2.5 times more likely to be cured 
compared with those without infiltrative lesions (OR: 2.50; 95% CI: 1.03-6.08; p = 0.044). 
Cavitary changes on chest x-ray was associated with decrease likelihood of cure compared 
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with other x-ray findings (OR: 0.67; 95% CI: 0.51-0.89; p = 0.006). There was a statistically 
significant interaction term between gender and timing of ART. Males who were on ART 
prior to MDR-TB treatment were 2.1 times more likely to be cured compared with females 
started on ART after initiating MDR-TB treatment (OR: 2.12; 95% CI: 1.22-3.69; p = 0.008).  
Patients with normal haemoglobin level were twice as likely to be cured compared with those 
who were severely anaemic (OR: 2.02; 95% CI: 0.90-4.51; p = 0.087). 
3.6.2 Multivariable logistic model 
3.6.2.1 Socio-demographic/clinical factors 
Female patients on ART before commencement of MDR-TB treatment were 0.6 times less 
likely to be cured compared with females who were initiated on ART after the start of MDR-
TB treatment, adjusting for confounders such as age, BMI, co-morbidity, etc. (OR: 0.63; 95% 
CI: 0.39-1.02; p = 0.060) even though this was not statistically significant. Male patients on 
ART after commencement of MDR-TB treatment were 0.5 times less likely to be cured 
compared with females started on ART after MDR-TB treatment initiation, keeping all other 
covariates constant (OR: 0.46; 95% CI: 0.26-0.80; p = 0.006). Male patients who were on 
ART before commencement of MDR-TB treatment (OR: 2.97; 95%CI: 1.47-5.99; p = 0.002) 
were nearly three times as likely to be cured compared with females who were started on 
ART after MDR-TB treatment initiation, adjusting for age, BMI, co-morbidity, co-
trimoxazole prophylaxis, etc. See Appendix 8, Table 3.6.1 for predicted log-odds. 
Individuals aged 46 years and older were 1.7 times more likely to be cured compared with the 
younger age group (OR: 1.65; 95% CI: 1.05-2.59; p = 0.030).  Patients with CD4 cell count 
between “150-349” cells/m³ (OR: 1.85; 95% CI: 1.26-2.72; p = 0.002) and “≥350” cells/mm³ 
(OR: 1.76; 95%CI: 1.02-3.04; p = 0.043) were more likely to be cured compared with 
patients with CD4 cell count <150 cells/m³ (See Table 3.4). Those who had cavitary changes 
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on chest x-ray were 0.6 times less likely to be cured compared with patients with other x-ray 
findings (OR: 0.55; 95% CI: 0.39-0.79; p = 0.001). There was a decrease in likelihood of cure 
for patients who were placed on individualised regimen at baseline compared with patients on 
standardised regimen (OR: 0.62; 95% CI: 0.42-0.92; p = 0.016).  
There was no evidence of lack of fit of the model (Hosmer-Lemeshow goodness-of-fit p = 
0.359). There was no evidence of misspecification of the model (p = 0.653). BMI and 
haemoglobin were correctly modelled as linear terms (non-linearity p = 0.063 and 0.158 
respectively). There was no evidence of multi-collinearity as the VIF and tolerance levels 
were within normal ranges.  Sensitivity analysis was done with observations with high 
Pearson residuals and high leverage removed and model did not differ significantly from that 
with intact observations.  
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Table 3.4: Predictors of cure in HIV positive adults on treatment for MDR-TB at Sizwe 
Tropical Disease Hospital, Johannesburg. 
  ᵃUnivariable Analysis ᵇMultivariable Analysis 
Factor  Unadjusted 
OR 
Confidence 
interval 
p-value Adjusted 
OR 
Confidence 
interval 
p-value 
ART regimen             
After 1.00 Ref   1.00 Ref   
Prior 1.05 0.79-1.38 0.733 0.63 0.39-1.02 0.060 
Gender             
Female 1.00 Ref         
Male 0.92 0.70-1.20 0.528 0.46 0.26-0.80  0.006* 
ART regimen#gender             
After#Females 1.00 Ref   1.00 Ref   
Prior#Males 2.12 1.22-3.69 0.008* 2.97 1.47-5.99 0.002* 
Age groups             
18-45 1.00 Ref   1.00 Ref   
46-76 1.59 1.13-2.45 0.008* 1.65 1.05-2.59  0.030* 
District             
Westrand 1.00 Ref         
Sedibeng 0.90 0.49-1.67 0.738       
Tswhane 0.85 0.53-1.39 0.524       
Ekhurhuleni 0.63 0.39-1.01 0.056       
City of Johannesburg 0.63 0.41-0.99 0.043*       
Metsweding 0.89 0.20-3.93 0.881       
Race             
Other 1.00 Ref         
Black 0.57 0.19-1.71 0.314       
Employment status             
Employed 1.00 Ref         
Unemployed 0.75 0.56-1.02 0.063       
Categories of MDR-TB             
Category I (New) 1.00 Ref         
Category II 0.88 0.63-1.22 0.444       
Category III 1.02 0.67-1.58 0.898       
Pre-treatment smear status             
Negative 1.00 Ref         
Positive 0.80 0.59-1.07 0.136       
Not available 0.72 0.45-1.53 0.171       
Site of TB             
Pulmonary 1.00 Ref         
Extra-Pulmonary + Pulmonary 0.86 0.60-1.23 0.398       
BMI (kg/m²) 1.03 0.99- 1.07 0.134 1.00 0.95-1.05 0.996 
Co-trimoxazole Prophylaxis             
No 1.00 Ref   1.00 Ref   
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Yes 1.39 0.74-2.61 0.302 1.43 0.70-2.91 0.320 
CD4 Categories (cell/mm³)             
<150 1.00 Ref   1.00 Ref   
150-349 1.42 1.05-1.92 0.023* 1.85  1.26-2.72 0.002* 
≥350 1.58 1.05-2.38 0.028* 1.76  1.02-3.04  0.043* 
Haemoglobin (g/dl) 1.07 1.01-1.34 0.030* 0.98 0.90-1.07  0.707 
Infiltrative changes on chest 
radiograph             
No 1.00 Ref         
Yes 2.50 1.03-6.08 0.044*       
Cavitary changes on chest 
radiograph             
No 1.00 Ref   1.00 Ref   
Yes 0.67 0.51-0.89 0.006* 0.55  0.39-0.79 0.001* 
Fibrotic changes on chest 
radiograph             
No 1.00 Ref         
Yes 0.83 0.57-1.22 0.344       
Other Opportunistic Infections           
No 1.00 Ref         
Yes 0.66 0.49-0.89 0.007*       
Comorbidity             
No 1.00 Ref   1.00 Ref   
Yes 0.59 0.38-0.91 0.018*  0.61 0.35-1.08 0.092 
Adverse events             
No 1.00 Ref         
Yes 1.06 0.81-1.40 0.668       
Regimen type at baseline             
Standardised 1.00 Ref   1.00 Ref   
Individualised 0.67 0.49-0.91 0.012* 0.62 0.42-0.92  0.016* 
*Significant p-values; OR: Odds ratio; ART regimen#gender: Interaction between timing of ART and 
gender;  
Hosmer-Lemeshow Goodness-of-fit test p = 0.359;  
Model specification test p = 0.653; 
ᵃUnadjusted models; ᵇAdjusted for age, BMI, co-morbidity, CTX prophylaxis.     
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3.7 Predictors of failure 
3.7.1 Univariable Poisson regression analysis 
3.7.1.1 Clinical factor 
The only factor that was associated with failure during the univariable analyses was 
individualised regimen at baseline (see Table 3.5). Compared with standardised regimen at 
baseline, patients on individualised regimen at baseline had over two times the higher rate of 
failure (IRR: 2.48; 95% CI: 1.18-5.20; p = 0.016). 
3.7.2 Multivariable Poisson analysis 
3.7.2.1 Clinical factors 
There was no statistically significant relationship between receiving ART prior to MDR-TB 
treatment and incidence rate ratio of failure (IRR: 0.75; 95% CI: 0.33-1.73; p = 0.504), 
keeping all other covariates constant. Patients with severe anaemia had nearly 4 times higher 
rate of failure compared with patients with normal haemoglobin level (IRR: 3.94; 95% CI: 
1.20-12.89; p = 0.024). Patients on individualised regimen at baseline had a 2.3 times higher 
rate of failure compared with patients on standardized regimen at baseline (IRR: 2.25; 95% 
CI: 1.02-4.95; p = 0.045). There was a trend with factors such as presence of co-morbidity 
(IRR: 2.20; 95% CI: 0.95-5.11; p = 0.067) and cavitary lesions on chest x-ray (IRR: 2.12; 
95% CI: 0.93-4.83; p = 0.075) with p-values greater than 0.05, but less than 0.1 to be 
predictors of failure (see Table 3.5). There were no highly correlated variables during the 
assessment of multi-collinearity. Haemoglobin and BMI were modelled as linear terms as 
non-linearity p-values were 0.553 and 0.570 respectively. There was no evidence of 
specification error (p = 0.969) nor lack of fit of the model (Pearson goodness-of-fit p = 
0.504).  
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Table 3.5: Predictors of failure in HIV positive adults on MDR-TB treatment at Sizwe 
Tropical Disease Hospital, Johannesburg. 
  ᵃUnivariable Analysis  ᵇMultivariable Analysis  
Factor  
Unadjusted 
IRR 
Confidence 
interval 
p-value 
Adjusted 
IRR 
Confidence 
interval 
p-value 
ART regimen             
After 1.00 Ref   1.00 Ref   
Prior 0.98 0.47-2.00 0.965 0.75 0.33-1.73 0.504 
Age groups             
18-45 1.00 Ref         
46-76 0.79 0.27-2.28 0.662       
Gender             
Female 1.00 Ref         
Male 0.93 0.44-1.96 0.854       
Employment status             
Employed 1.00 Ref         
Unemployed 0.94 0.41-2.13 0.875       
Categories of MDR-TB             
Category I (New) 1.00 Ref   1.00 Ref   
Category II 2.05 0.71-5.95 0.186 1.58 0.49-5.16 0.446 
Category III 0.67 0.12-3.67 0.647 0.44 0.05-4.08 0.669 
Pre-treatment smear status             
Negative 0.61 0.15-2.53 0.492       
Positive 1.35 0.40-4.55 0.627       
Not available 1.00 Ref         
Site of TB             
Pulmonary 1.00 Ref         
Extra-Pulmonary + 
Pulmonary 0.77 0.27-2.21 0.624       
BMI 0.97 0.87-1.07 0.547 1.01 0.93-1.09 0.893 
Co-trimoxazole Prophylaxis             
No 1.00 Ref   1.00 Ref   
Yes 0.88 0.21-3.70 0.857 1.59 0.25-10.30 0.626 
CD4 (Cells/mm3)             
<150 0.76 0.29-1.96  0.569       
150-349 0.43 0.15-1.29  0.134       
≥350 1.00 Ref         
Haemoglobin (g/dl)              
Severe Anaemia (<7.0) 2.69 0.78-9.30 0.117 3.94 1.20-12.89 0.024* 
Moderate Anaemia (7.0-9.99) 1.09 0.46-2.57 0.839 0.96 0.40-2.31 0.922 
Mild Anaemia (10-10.99) 0.43 0.10-1.87 0.260 0.25 0.03-1.78 0.164 
Normal (≥11) 1.00 Ref   1.00 Ref   
Infiltrative changes on chest 
radiograph             
No 1.00 Ref         
Yes 1.01 0.14-7.47 0.990       
Cavitary changes on chest             
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radiograph 
No 1.00 Ref   1.00 Ref   
Yes 1.81 0.85-3.87 0.125 2.12 0.93-4.83 0.075 
Fibrotic changes on chest 
radiograph             
No 1.00 Ref         
Yes 1.36 0.41-4.50 0.620       
Other Opportunistic Infections           
No 1.00 Ref         
Yes 0.94 0.43-2.08 0.878       
Comorbidity             
No 1.00 Ref   1.00 Ref   
Yes 1.79 0.72-4.41 0.207 2.20 0.95-5.11 0.067 
Adverse events             
No 1.00 Ref   1.00 Ref   
Yes 0.54 0.24-1.23 0.142 0.50 0.22-1.44 0.100 
Regimen type at baseline             
Standardised 1.00 Ref   1.00 Ref   
Individualised 2.48 1.18-5.20 0.016* 2.25 1.02-4.95 0.045* 
IRR- Incidence rate ratio; *Significant p-values; Pearson goodness-of-fit p = 0.504;  
Model specification test p = 0.969   
ᵃUnadjusted models; ᵇAdjusted for Co-trimoxazole prophylaxis.       
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CHAPTER 4: DISCUSSION 
4.1 Introduction 
The demographic, clinical characteristics and outcomes of MDR-TB in HIV co-infected 
patients at Sizwe Tropical Disease Hospital were examined based on timing of ART 
initiation, as well as predictors of mortality, cure and failure. A total of 1,137 patients were 
included in the preliminary analyses with the proportion of patients with no history of 
previous TB and MDR-TB treatment (primary MDR-TB) among this population being 
22.9%. The median duration from report of MDR-TB by the NHSL to start of MDR-TB 
treatment (treatment-initiation-delay) was 10 days with an IQR of 4-21days. This is 
remarkably lower than the treatment-initiation-delay of 72 and 93 days for decentralised and 
centralised settings respectively documented previously in a South African study (35). This 
finding is critical to help limit the spread of MDR-TB in the population, by setting up 
appropriate follow-up strategies from the point of diagnosis to start of treatment. Among the 
83.3% of patients confirmed to be on ART during treatment of MDR-TB, 47.9% of them 
were on ART prior to MDR-TB treatment, while 35.4% were on ART after commencing 
MDR-TB treatment. 
 The overall proportion of patients who died was 22.7% similar to the proportion of mortality 
reported in previous South African studies (16) and is comparable to 17% reported in India 
(38), but substantially different from 57% noted by Palacios E et al. in Peru (36). The overall 
proportion of successful treatment was 46.4% akin to that noted in South Africa (16-18) and 
48% noted in India (38), but lower than the 61.9% in Lesotho (20). The percentage of cure 
which was 29.8% was comparable to the 21% documented in Peru (36). Patients who failed 
treatment made up 2.9% of the entire cohort, lower than the 5-8% documented in a meta-
analysis by Johnston JC et al. (31) and over the 9% by other studies (16, 38). In this study, a 
high proportion of default (22.3%) was noted and it is comparable to previous South African 
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studies (16) and to the 26% noted in India (38). Restricting the analysis to those who died and 
were on ART before or after commencement of MDR-TB treatment, the proportion of 
mortality (21.8% vs. 15.4%) was higher for those on ART prior to MDR-TB treatment 
initiation. 
Predictors of mortality, cure and failure were determined during multivariable analyses 
adjusting for all potential confounders. The following factors were significantly associated 
with mortality: the use of ART prior to commencement of MDR-TB treatment, being 
severely underweight and underweight, cavitary lesions on baseline chest x-rays, the presence 
of other opportunistic infections and other co-morbidities. For predictors of cure, there was a 
significant interaction term between timing of ART and gender. Factors that positively 
predicted cure were male patients on ART prior to commencement of MDR-TB, patients 
aged 46years and older, and patients with CD4 counts between “150-349” and” ≥350” 
cells/mm³. Negative predictors of cure included: males on ART after commencement of 
MDR-TB treatment, presence of cavitary lesions on baseline chest x-rays, and modified 
individualised regimen at baseline.  Significant risk factors for failure included: severe 
anaemia (haemoglobin level <7g/dl) and modified individualised regimen at baseline. 
4.2 Systematic overview of the study findings 
4.2.1 Predictors of mortality 
ART use prior to MDR-TB treatment initiation was significantly associated with higher odds 
of mortality compared with ART initiation after commencement of MDR-TB treatment. This 
finding has not been reported before by other studies. Based on this data, a greater percentage 
of patients who commenced ART before MDR-TB treatment initiation were severely 
underweight (15.4%). They also had more extra-pulmonary TB (20.7%), adverse events 
(45.2%), and modified regimen based on patients’ history at baseline (31.5%) compared with 
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patients who started ART after initiation of MDR-TB treatment. This is surprising as it 
should be assumed that patients should have benefited from being on ARVs before MDR-TB 
treatment. On the other hand, if this protective benefit of ARVs was in effect, these patients 
should not have developed MDR-TB in the first instance. It is likely that poor adherence from 
drug side effects leading to problems of drug resistance and virological failure may have been 
responsible for this trend.  
This result poses questions on the issue of adherence to ART for patients who were already 
on ART prior to MDR-TB treatment in a country like South Africa with majority of her HIV 
positive patients on ARVs. Additionally, overlapping drug toxicities from the MDR-TB and 
ARVs pills may have resulted in the high mortality in this study. There was less likelihood of 
mortality in patients on ART post MDR-TB treatment initiation, even though more patients 
on ART after commencement of MDR-TB treatment had other non-TB opportunistic 
infections (26.6% vs. 42.9%). This could be due to the fact that on starting ARVs there was 
improved immune reconstitution coupled with the tight adherence counselling, close 
monitoring and management of adverse events at Sizwe Hospital; hence resultant decrease in 
mortality. 
This study found that being severely underweight and underweight were risk factors of 
mortality, and demonstrated a biologic gradient with patients who were severely underweight 
having a higher likelihood of mortality (OR: 3.46) compared with those who were 
underweight (OR: 2.31).  These findings are similar to previous studies (16, 20, 31, 36, 41, 
42). In this cohort, 43.5% of the patients were severely underweight and underweight. HIV 
and TB are linked to malnutrition (41) and wasting syndrome is a hallmark of severity of TB 
and HIV infection, therefore its strong association as a predictor of mortality irrespective of 
patients’ ART status.   
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Analysis revealed that the presence of cavitary lesions on chest x-ray at baseline was a risk 
factor of mortality. There have been conflicting studies on the role of cavitation on chest x-
ray as a risk factor of poor outcomes. Some studies have linked the presence of cavitation on 
chest with longer culture conversion time; a surrogate marker for poor outcomes (43-45), 
while others have found no statistically significant relationship between cavitation and poor 
outcomes (31, 46). In a recent study done by Brust JC et al. in South Africa, its failure of 
finding a significant relationship between cavitation and longer time to sputum conversion 
may have been due to the limited sample size of 56 patients (46). 
The presence of other non-TB opportunistic infections was a significant factor that 
consistently predicted mortality both in univariable and multivariable analyses. This finding 
has not been reported before by other studies beyond the descriptive level (36). There is a 
higher risk of mortality and development of other opportunistic infections in HIV-TB co-
infected patients (50, 51). The role of other non-TB opportunistic infections is important in 
the clinical and prognostic staging of HIV positive patients. Serious opportunistic infections 
like Kaposi sarcoma, cervical cancer, CMV infections, HIVAN, etc. are already an indicator 
of the depressed immunity with an increase likelihood of mortality masking the importance 
of timing of ART initiation in these patients.  
In this study the presence of co-morbidities as listed in the methods section was a significant 
risk factor of mortality. This result was also noticed in a recent study in the United Kingdom 
(47). There is an established “bidirectional synergistic” relationship between TB HIV co-
infection and development of co-morbidities like DM (52-54). Treatment of HIV with ART 
especially with the protease inhibitors is associated with hyperglycaemia, insulin resistance, 
dyslipidaemia (55); not only leading to the development and complication of DM, but cardio-
vascular, cerebro-vascular, hepatic and renal problems. Most studies done on the role of 
certain co-morbidities on TB mortality focus on single disease entity like DM; with positive 
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(56) and negative (31) results. This study is the first in South Africa to in-corporate the 
presence of other non-communicable co-morbidities apart from DM to assess its impact on 
mortality in MDR-TB HIV co-infected patients, especially with the emerging link of 
infectious and non-communicable diseases.  
4.2.2 Predictors of cure 
Based on this data, male patients on ART prior to initiation of MDR-TB treatment were more 
likely to be cured compared with female patients commenced on ART after initiating MDR-
TB treatment. The interaction between timing of ART and gender was significant 
nonetheless, neither of each factor (timing of ART nor gender) was significantly associated 
with cure. While exploring this relationship, it was noticed that the log-odds (hence the 
likelihood) of cure in females who started ART prior to MDR-TB treatment decreased 
rapidly by 1.08 times compared with those initiated on ART after commencement of MDR-
TB treatment. Among male patients started on ART before MDR-TB treatment, there was an 
increase in the log-odds by 0.55 times compared with males on ART after commencement of 
MDR-TB treatment. The reason for this finding is unclear and surprising. Male gender has 
been associated with poor successful TB outcome (31, 39, 57), compared with female gender. 
But in these studies timing of ART initiation was not considered.  
There have been contradicting evidence on the effect of gender on ART adherence, but in an 
extensive literature review to determine the existence of gender differences on non-adherence 
over an 11 year period in developed countries, female gender predicted poor adherence to 
ART (58). More so, in our study females were younger than males; with 53.2% (494) of 
females in age group 18-45 years compared with 63.2% of males in age group 46-76 years 
and more females 51.6% were on ART prior to commencement of MDR-TB treatment 
compared with males. Older adults have been shown to have better adherence compared with 
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younger adults (59-61). The age differentials may have impacted on gender of patients 
modifying the relationship between timing of ART and cure.  
Reduced adherence to ART in females have also been linked to depressive symptoms (62, 
63) and lack of supportive interpersonal relationships (64). A study done in South Africa 
showed that about 70% of the MDR-TB households were headed by females (65) who are 
faced not only with the challenges of life-long effects of HIV and ART coupled with the long 
term treatment duration and follow-up required for MDR-TB but also with the  arduous task 
of child-bearing and rearing. These huge responsibilities may have poorly affected the 
adherence of females who were on ART prior to commencement of MDR-TB treatment as 
such the overall effect on cure. 
The data revealed that patients aged 46 years and older had a higher odds of cure compared 
with those from the younger age group. About 18.2% of the cohort were adults aged 46 years 
and older. In a study by Chan ED et al., older adults on fluoroquinolone therapy had higher 
likelihood of successful treatment (66). There is a correlation between increasing age and 
positive adherence to ART, especially for adults’ ≥50 years of age (59-61). This finding may 
have positively affected adherence to anti-TB medications; hence a higher likelihood of cure 
in these group of patients.  
Patients with CD4 cell counts in the group of “150-349” and “≥350” cells/mm³ were 
significantly more likely to be cured compared with patients with CD4 “<150” cells /mm³. In 
this cohort, 35% and 17% of patients were in the above significant CD4 categories 
respectively. The relationship between increasing CD4 and cure has not been reported by 
others, even though CD4 count <200 cells/mm³ has been shown to be a predictor of 
unsuccessful outcomes in MDR-TB (40) and in XDR-TB patients (67). Thus with early HIV 
diagnosis, timely commencement of ARVs and maintenance of strict adherence, it should be 
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anticipated that an increase CD4 count and invariably improved immunity and virological 
suppression will result in improved favourable treatment outcomes.  
This research also established that patients with cavitation on chest x-ray at baseline were less 
likely to be cured compared with those without cavitary lesions. Cavitation on chest x-rays 
are particularly seen in HIV co-infected patients with higher CD4 count of ≥200 cells/mm³ 
(68), and is indicative of high bacillary load (69) and likelihood of smear positivity (70). This 
result is consistent with other studies (43-45) establishing the association between cavitation, 
longer time to sputum conversion and hence decrease likelihood of cure and inevitably poor 
successful outcome. Additionally in this study cavitary lesions also predicted higher odds of 
mortality, which further strengthens its relationship with unsuccessful outcomes. 
The study found that patients with modified individualised regimen at baseline were less 
likely to be cured compared with patients on standardised regimen. Contrary to this findings, 
most studies have found individualised regimen compared with standardised regimen to be 
associated with successful outcome (30, 41), though the meta-analysis findings by Orenstein 
EW et al. did not detect a statistically significant difference between the two groups. This 
disparity is not surprising because in our context, treatments were modified at baseline based 
on existing co-morbidities, adverse events and extensive resistance pattern including pre-
XDR strains, but not based on DST results only. In view of this fact, modifying treatment 
may have impacted on the time to culture conversion and hence the proportion of patients 
cured.  
4.2.3 Predictors of failure 
Severe anaemia (haemoglobin <7.0mg/dl) at baseline was a predictor of treatment failure 
during the multivariable analysis. The cause of anaemia in MDR-TB HIV co-infected 
patients are multi-factorial, resulting from the HIV/mycobacterial infection and treatment 
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with both anti-TB and ARV medications. This finding is consistent with that of Mitnick C, et 
al. where low haematocrit was associated with about 4 times increase in the hazard of failure 
or death compared with normal haematocrit (41). This result is important because it will act 
as a reminder to physicians in the management of TB/HIV co-infected patients by 
encouraging balanced nutrition and optimization of haemoglobin levels while on treatment. 
Modified individualised regimen at baseline for patients based on co-morbidities and 
adverse-events was significantly associated with treatment failure. For these patients some 
drugs were delayed at baseline pending improvement in clinical condition. This supports the 
result by Leimane V et al. which noticed that patients on ≤ 5 drugs for 3 months or more were 
more likely to fail or die (42). This is analogous to the results seen during the multivariable 
analysis for predictors of cure, where patients on individualised regimen at baseline had a 
lower likelihood of cure.  Even though this study revealed a marginally significant 
relationship between cavitation on chest x-ray (p = 0.08) and the presence of co-morbidity (p 
= 0.07) with treatment failure, there was a significant association between these factors and 
mortality. This further supports the plausibility of these factors being responsible for poor 
outcomes. 
4.3 Potential study biases 
4.3.1 Collection of exposure and outcome data 
Self-report of ART status by some of the patients who started ART before commencement of 
MDR-TB treatment would have presented a likelihood of information bias; but ART status of 
individuals were confirmed on referral letters or telephonically by contacting referral clinics 
where patients were initiated on ART and by inspection of pills.  Observer bias was 
minimised during data collection by first ascertaining the outcome before determining the 
ART status of the patient. Instrument bias may have occurred while measuring some of the 
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clinical exposure variables like height, weight, etc. Nevertheless, repeat measurement of 
other exposure variables, like CD4, haemoglobin, etc., and ascertainment of HIV status by 
the NHLS where results were discrepant helped to minimise misclassification of patients 
based on the exposure variables. 
Selection bias was minimised by including only confirmed HIV positive adults and also 
excluding patients not on ART and those with unavailable ART status during MDR-TB 
treatment. Patients who started ART after completing MDR-TB treatments were not included 
as exposed to ART during treatment to avoid over-estimation of the effect of ART use after 
initiating MDR-TB treatment on the outcomes. Patients with mono/poly resistance were also 
excluded as these were not truly MDR-TB cases. Outcomes were objectively measured, 
avoiding misclassification bias as majority of patients were confirmed cured or failed 
treatment based on DST from NHLS and extensive follow-up. Mortality was also confirmed 
in the hospital and for patients who died at home, regular tracing and reminders for visits 
helped in ascertaining home-related mortality.  
4.3.2 Residual confounding and missing data of some of the exposure variables 
Exposure variables were correctly stratified and univariable analyses were done and factors at 
a p <0.1 were considered covariates for inclusion in the multivariable models which adjusted 
for several factors to limit residual confounding. Factors at p <0.05 were considered as 
significant predictors of mortality, failure or cure. As such, the strength of association 
between the main exposure variable, other covariates and each outcome may not have been 
due to chance. 
This study depended on already collected data from medical records, hence may not have 
measured all the possible confounders. Viral load for patients would have been a true test of 
adherence especially for patients on ART prior to initiating MDR-TB treatment, thereby 
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helping in the explanation of the relevant findings. However, viral load could not be used as 
the definition of virological suppression varied over the years according to the NHLS 
definitions and also few data were collected for this variable. Baseline data on height were 
not collected completely especially for the first two years of the study, resulting in missing 
variables for BMI of about 19% of cases. Dates for ART initiation were not completely 
documented for most patients who started ART before commencement of MDR-TB 
treatment, hence imputation of complete data was done to help ascertain the duration for 
which patients were on ART. Data on occupation of the patients were limited to employed or 
un-employed and this did not allow for risk assessment of certain occupations on MDR-TB.  
4.4 Study limitations 
In this study, timing of ART was stratified as before or after commencement of MDR-TB 
treatment and this may not allow proper assessment of the effect of duration of ART on the 
outcomes. Some patients may have been on ART long before MDR-TB treatment initiation, 
while others may have commenced ART just before the start of MDR-TB treatment. 
Information on baseline ART regimen were not collected, as this would have been a pointer 
to drug resistance and virological failure and could have possibly helped in explaining the 
role of timing of ART on mortality and cure. 
Some of the data on other opportunistic infections, co-morbidity, adverse events, height, and 
weight were not documented in the case notes, hence assumed to be missing. This may have 
affected the statistical power to detect such variables as significant predictors during the 
multivariable analyses. Coding co-morbidities as a yes or no variable instead of looking at 
individual diseases may have overestimated the effect of such on the outcomes in patients 
who had one or two co-morbidities compared to those who had a combination of highly fatal 
co-morbidities.  
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Different guidelines were used through the years for initiation of ART in MDR-TB treatment 
(prior to 2010, CD4 of <350 cells/mm³; while in 2010 compulsory initiation as soon as 
patient can tolerate ART irrespective of the CD4 count). This may have affected the 
outcomes over the years, with poorer outcomes before the present policy was effectively put 
to practice. Also change of MDR-TB regimen from ofloxacin to moxifloxacin, with all 
patients not subjected to the same drugs over time may have affected the outcomes too. Using 
baseline clinical variables like CD4, haemoglobin, and even weight which are known to be 
time varying as predictors of the 3 major outcomes, may not give a true picture of the 
association with the outcome (as these covariates may decrease or increase over time).  
Using cure alone without merging with “treatment completed” may have resulted in under-
estimation of the total proportion of the patients cured. There might have been a higher 
percentage of cure, but most patients do not send back their follow-up DST results to Sizwe 
(lost to follow-up after completing treatment) and these may have been missed. However, the 
strength with using cure only is that these patients were actually confirmed cured through 
micro-biologic results and extensive follow-up over a period of time. 
Data on cause-specific mortality were not collected. Some patients may have died due to the 
presence of other co-morbidities and opportunistic infections other than MDR-TB. The 
quality of data collected at Sizwe improved over the years, however, information were poorly 
recorded in the early years (2007/2008). 
4.5 Study strengths  
The study used retrospectively collected data on exposure variables which preceded the 
outcomes of MDR-TB, hence credible in temporality. Patients initiated on ART at Sizwe 
Hospital had definite start dates and so were not likely to be misclassified as those who 
started ART prior to commencement of MDR-TB treatment. It is also a standard practice at 
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Sizwe Hospital for physicians to ascertain the ART status of patients at baseline, reducing the 
likelihood of misclassification bias in the exposure groups.   Good follow-up on ART 
treatment via repeated adherence counselling and drug monitoring were done once patients 
commenced MDR-TB treatment at Sizwe hospital and adverse events were monitored, 
documented and treated by managing physicians.  
This study reported final outcomes of MDR-TB among a cohort of HIV positive patients after 
at least a two year follow-up period hence unlikely to under-estimate the outcomes. This is 
one of the largest cohort of MDR-TB HIV co-infected patients, allowing reasonable power to 
detect a difference between the two exposure groups in relation to the major outcomes and 
other risk factors for mortality, cure and failure. Certain variables like weight, height, CD4 
count, haemoglobin, and chest x-rays were collected within specified periods to prevent 
disparate exposure duration hence, preventing over or under-estimation of the effect size. 
Information on certain exposures like other opportunistic infections, co-morbidity and 
adverse events were collected and this may have helped to explain the predictors of mortality, 
cure and failure.  
4.6 Generalizability  
South Africa is among one of the countries with very wide ART coverage, hence these results 
should be interpreted with caution as they may not be generalizable to regions with low ART 
coverage. This study was done in Gauteng province and findings may not be generalizable to 
other provinces as MDR-TB/HIV co-infection prevalence may be different for different 
provinces. 
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CHAPTER 5: CONCLUSION AND RECOMMENDATIONS 
5.1 Conclusion 
In conclusion, outcomes of MDR-TB did not differ significantly between the two ART 
groups except for mortality which was significantly higher among those who started ART 
before commencement of MDR-TB treatment. Factors predicting high mortality included the 
use of ART before commencement of MDR-TB treatment, being severely underweight and 
underweight, cavitary lesions on baseline chest x-ray, the presence of other opportunistic 
infections, and other co-morbidities. Gender significantly modified the relationship between 
timing of ART initiation and cure. Positive predictors of cure included males on ART prior to 
commencement of MDR-TB treatment, patients aged 46 years and older, and those with CD4 
count between “150-349” and ≥350 cells/mm³. Factors negatively predicting cure included: 
cavitary lesions on baseline chest x-rays, and modified individualised regimen at baseline. 
Risk factors of treatment failure included: severe anaemia and modified individualised 
regimen at baseline.  
5.2 Recommendations 
In summary, the study findings of predictors of mortality, cure and failure in MDR-TB HIV 
co-infected patients as outlined above are valid and unlikely to be due to chance, sampling 
bias or residual confounding. This work is unique as it provides new information while also 
reinforcing old knowledge to clinicians and public health practitioners for the identification 
of TB populations at higher risk of death, treatment failure and decreased cure.  
The lower MDR-TB treatment-initiation-delay of 10 days at a centralised facility like Sizwe 
Hospital highlights that interventions put in place for strict follow-up and early initiation of 
MDR-TB treatment is effective and highly commendable. Strides at shortening this time 
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further is necessary, in order to continually reduce the spread of drug resistant MTB in the 
population.  
Findings supportive of high mortality in patients who were already on ART before 
commencement of MDR-TB treatment raise concerns on general ART adherence and 
monitoring at different HIV clinics across Gauteng Province, which should be re-visited. 
Strict adherence to ART in HIV positive patients irrespective of their TB status is needful to 
prevent further deterioration in their immune status and development of MDR-TB and other 
severe opportunistic infections.  
Clinicians should not undervalue the role of adherence to ART treatment in patients who are 
already on ART before commencement of MDR-TB treatment. Appropriate management of 
already existing adverse events, opportunistic infections and co-morbidities in these patients 
is important to maximise the benefits of being on ART before commencement of MDR-TB 
treatment, and on the whole achieve better treatment outcomes.  
The study results also places an emphasis on the role of Public health practitioners to 
intensify gender and age-specific intervention programmes (behavioural and biological) 
targeted at increasing adherence and drug monitoring for HIV infected patients (especially 
among females and younger adults).  
This work  also confirms that timely (early) initiation of ART in MDR-TB patients, strict 
adherence counselling and treatment monitoring, early diagnosis and management of adverse 
events and other co-morbidities would decrease mortality, resulting in better treatment 
outcomes (20, 36, 48). 
In a broader perspective, the findings of this study calls for governmental, non-governmental, 
inter-sectorial and public health collaborations in providing appropriate health funding for 
61 
 
public health policies on preventive and  other intervention programmes to lower the  risk 
factors for mortality, poor successful treatment and failure in this vulnerable population.  
5.3 Suggestions for further studies 
Based on the above findings, further research should be done using biologic parameters like 
baseline virological suppression for patients on ART prior to commencement of MDR-TB 
treatment to assess their adherence level to ART, and comparing treatment outcomes with 
those that started ART after MDR-TB treatment initiation to assess if this has a role in the 
increase risk of mortality in these group of patients.  
Another important areas for research include the need to understand clearly the reason why 
males who were on ART prior to MDR-TB treatment were more likely to be cured, compared 
with females and assessment of  behavioural and biologic factors that impact negatively on 
ART adherence in females.  
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Appendix 4 
Table 3.2.1: Bivariate analysis of demographic characteristics of MDR-TB HIV co-
infected adults based on exposure to ART before or after commencement of MDR-TB 
treatment.  
Factors 
ART prior to 
commencement 
of MDR-TB 
treatment 
ART after 
commencement 
of MDR-TB 
treatment Test Statistic p-value 
  N (%) (N = 545) N (%) (N = 402)     
Age 36 (31-43)* 35.5 (31-42)*  z =  -0.587 0.557 
Age groups         
18-45 448 (82.2) 334 (83.1) chi = 0.125 0.723 
46-76 97 (17.8) 68 (16.9)     
Gender         
Male 264 (48.4) 193 (48.0) chi = 0.017 0.896 
Female 281 (51.6) 209 (52.0)     
District         
Westrand 58 (10.6) 54 (13.4) Fisher's Exact 0.585 
Sedibeng 39 (7.2) 30 (7.5)     
Tswhane 102 (18.7) 79 (19.7)     
Ekhurhuleni 124 (22.8) 95 (23.6)     
City of Johannesburg 216 (39.6) 142 (35.3)     
Metsweding 6 (1.1) 2 (0.5)     
Race         
Other 6 (1.1) 7 (1.7) Chi = 0.701 0.403 
Black 539 (98.9) 395 (98.3)     
Employment status         
Employed 149 (27.3) 109 (27.1) Chi = 0.006 0.939 
Unemployed 396 (72.7) 293 (72.9)     
N- Total number in each group; % - Column percentages;      
*Median and Inter-quartile range (IQR);  
Test statistic based on chi-square, Fisher’s Exact and Wilcoxon Rank-sum tests. 
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Appendix 5 
 
Figure 3.3: ART status of patients on treatment for MDR-TB at Sizwe Tropical Disease 
Hospital, Johannesburg from 1
st
 January, 2007 to 31
st
 December, 2010. “No”- Not on ART, 
“NA”- ART information not available, “After”- Initiated on ART after commencement of 
MDR-TB treatment, “Prior”- Initiated on ART before commencement of MDR-TB treatment. 
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Appendix 6 
 
 
 
Figure 3.4: Duration on ART treatment in HIV positive MDR-TB patients at Sizwe Tropical 
Disease Hospital, Johannesburg. 
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Appendix 7 
 
 
 
Figure 3.5 Tab-plots of MDR-TB outcomes by timing of ART initiation showing frequency 
and proportion of patients in each outcome category. S “Still on treatment”; TO 
“Transferred-out”; TD “Treatment Defaulted”; TC “Treatment Completed”; and TF 
“Treatment Failure”. 
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Appendix 8 
Table 3.6.1: Predicted log-odds of the interaction term between timing of ART initiation 
and gender 
.predict logitmfit, xb 
. table artreg_new gender, c(mean logitmfit) 
-------------------------------- 
Time of | 
ART      | 
initiatio |        Gender        
n           |      Male     Female 
----------+--------------------- 
    After | -1.129898  -.3676776 
    Prior | -.5102376  -.7653566 
The log-odds (hence the likelihood) of cure decreases more rapidly in females on ART prior 
by -1.08times compared to females on ART after commencement of MDR-TB treatment. For 
males, the log-odds of cure increases by 0.55times in those who were on ART prior 
compared to males on ART after commencement of MDR-TB treatment. 
Table 6.2: Predicted probabilities of the interaction term between timing of ART initiation 
and gender 
.predict mfit, pr 
.table artreg_new gender, c(mean mfit) 
------------------------------ 
Time of | 
ART      | 
initiatio |       Gender       
n           |     Male    Female 
----------+------------------- 
    After | .2556391   .4135338 
    Prior | .3837838   .327957 
